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Introduction 
Genomic DNA is under constant stress from both endogenous and exogenous sources.  
Factors such as UV light, chemotherapeutic agents, and even normal metabolic activities can all 
damage DNA by creating lesions; nitrogenous base alterations that include crosslinking, addition 
of covalent adducts, and spontaneous base loss. All forms of DNA damage are potentially 
detrimental because they hinder the cell’s ability to replicate DNA efficiently and accurately. 
Fortunately, the cell has many methods to minimize the effects of DNA damage. The damage 
can either be repaired or, if an unrepaired lesion stalls DNA replication, tolerated through lesion 
bypass. Because these pathways are the means by which genome integrity is maintained, they are 
very important to thoroughly understand(1). The studies reported herein concern two families of 
enzymes involved in the complex DNA damage response; the X- and Y-families of DNA 
polymerases. 
Chapter 1 focuses on the X-family DNA polymerases, which are primarily implicated in 
DNA repair pathways(2). Two X-family enzymes were selected and their ability to fill gaps in 
DNA characterized. Gap filling is an essential step of base excision repair, therefore this study 
contributed to knowledge of the two polymerases’ putative biological roles. The results of this 
study were also published in DNA Repair(3). In Chapters 2 and 3, the focus switches to the Y-
family DNA polymerases, which are primarily implicated in lesion bypass(4). These chapters 
report the mutagenic profile of cis-syn cyclobutane thymine dimer and cisplatin-dGpG lesion 
bypass by the human Y-family DNA polymerases as well as a model Y-family DNA polymerase 
from Sulfolobus solfataricus. It should be noted that the projects discussed in Chapters 2 and 3 
are ongoing and that the results reported are preliminary. 
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In this thesis, I discuss the three projects in which I had the most involvement during my 
time in Dr. Suo’s laboratory. This being said, each project was part of a larger collaborative 
effort and was undertaken with the guidance and assistance of other members of the lab. 
Therefore, as I discuss the results of each project I will try to highlight my own contribution and 
to acknowledge the hard work of others.    
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Chapter 1: An Investigation of the Gap-Filling Activity of Human 
DNA Polymerases Lambda and Beta 
Background 
 As stated in the Introduction, the cell’s response to DNA damage is very complex. All 
lesions are not repaired in the same way. In fact, there are several pathways through which the 
cell can repair damaged DNA. One of these pathways is base excision repair (BER). It is the 
predominant way in which single-base DNA lesions are repaired in mammals(5). In base excision 
repair, the damage is first recognized by a lesion-specific DNA glycosylase, which cleaves the 
glycosidic bond attaching the damaged nitrogenous base to its deoxyribose, generating an 
apurinic or apyrimidinic (AP) site. The phosphodiester backbone of DNA is then cleaved 
adjacent to the lesion by AP endonuclease I. The resulting gap in DNA is filled by a DNA 
polymerase, which also removes the 5’-deoxyribose phosphate (dRP) of the downstream strand 
with its dRP lyase domain. Finally, the phosphodiester backbone is sealed by a DNA ligase. 
Interestingly, the gap-filling step of BER can be accomplished in two ways - termed short-patch 
BER (SP-BER) and long patch BER (LP-BER). In SP-BER, the DNA polymerase incorporates 
only one nucleotide. In LP-BER, 2-10 nucleotides are incorporated, displacing the downstream 
strand. The downstream strand is then removed by flap endonuclease I(6). 
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Figure 1. A scheme of the general BER pathway(6). 
 In this study, we focused on the gap-filling step of BER. To perform this step, the DNA 
polymerase must be able to catalyze gap-filling DNA synthesis and must contain a dRPase 
domain. The two X-family DNA polymerases in this study, human DNA polymerase beta 
(hPolβ) and human DNA polymerase lambda (hPolλ), possess these abilities(7). hPolβ has been 
proven to perform SP-BER in vivo(8), and is there is also evidence that it functions in LP-BER(9). 
We chose to study hPolλ because it meets the above criteria for BER function and it shares 34% 
sequence similarity with hPolβ(10). hPolλ is also structurally similar to hPolβ, though hPolλ 
possesses N-terminal BRCT and proline-rich domains(11). Additionally, it has been proposed that 
hPolλ plays a complementary and/or supporting role to hPolβ in vivo(7). Motivated by this 
information, we completed a detailed pre-steady state kinetic analysis of gap-filling synthesis by 
hPolλ and hPolβ on DNA containing 1-10 nucleotide gaps. The goals of this study were as 
follows: 1) to determine the effect of gap size on DNA polymerase fidelity and incorporation 
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efficiency, 2) to observe the effect of hPolλ’s N-terminal BRCT and proline-rich domains on its 
ability to perform gap filling synthesis and, 3) to compare the gap-filling activities of hPolβ and 
hPolλ. 
Methods 
Materials: The following reagents were purchased for this project: OptiKinaseTM from 
USB Corporation, deoxyribonucleotide-5’-triphosphates from GE Healthcare, [γ-32P]ATP from 
MP Biomedicals, Bio-Spin 6 columns from Bio-Rad Laboratories, synthetic 
deoxyribonucleotides including a primer 21-mer, 5’-phosphorylated 19-mer, and template 41- to 
50-mers from Integrated DNA Technologies. Wildtype human DNA polymerase lambda 
(hPolλ), two N-terminal truncations of human DNA polymerase lambda (dPolλ, tPolλ), and 
human DNA polymerase beta (hPolβ) were expressed and purified for earlier studies as 
described previously(23). 
Construction of gapped DNA substrates: All synthetic deoxyribonucleotides purchased 
from Integrated DNA Technologies were purified using polyacrylamide gel electrophoresis and 
subsequently extracted and desalted for use. Concentration of the various deoxyribonucleotides 
was determined using UV spectroscopy at 260 nm. Deoxyribonucleotides were purified by 
various members of the Suo lab including two purified personally. David Beyer is to be thanked 
especially for the extensive DNA purification work he did for this project. The primer 21-mer 
was radiolabeled with [γ-32P]ATP using OptiKinaseTM. Unreacted [γ-32P]ATP was removed 
using Bio-Spin 6 size exclusion columns. Radiolabeling and removal of unreacted [γ-32P]ATP 
were both completed according to manufacturer’s directions. Gapped DNA substrates were 
constructed by mixing 5’-[32P]-radiolabeled 21mer, template 41- to 50-mer, and the 
	   9	  
complementary downstream 19-mer at a 1:1.15:1.25 molar ratio, respectively. This mixture was 
denatured by heating at 95C for 5 minutes, and annealing of deoxyribonucleotides was 
accomplished by cooling the mixture slowly to room temperature. The sequences of all annealed 
gapped substrates can be found in Appendix 1, Table 1.  
Single nucleotide incorporation assays: All kinetic assays on hPolλ, tPolλ, and 
dPolλ were performed in optimized buffer “L”; 50 mM Tris-Cl pH 8.4 at 37˚C, 5 mM MgCl2, 
100 mM NaCl, 0.1 mM EDTA, 5 mM dithiothreitol, 10% glycerol, and 0.1 mg/mL bovine serum 
albumin. All kinetic assays on hPolβ were performed in optimized buffer “B”; 50 mM Tris-Cl 
pH 7.8 at 37˚C, 5 mM MgCl2, 50 mM NaCl, 0.1 mM EDTA, 5 mM dithiothreitol, 10% glycerol, 
and 0.1 mg/mL bovine serum albumin. The listed concentrations are indicative of final 
concentrations after mixing all reaction components. Kinetic assays were performed at 37˚C. To 
begin each reaction, a pre-incubated solution containing radiolabeled gapped substrate and 
hPolλ (120 nM), tPolλ (120 nM), dPolλ (120 nM) , or hPolβ (300 nM) in the appropriate buffer 
was mixed with increasing concentrations of a single nucleotide (0.2-1500 µm). At various time 
points, aliquots of the reaction mixture were removed and quenched in EDTA to a final [EDTA] 
of 0.37 M. Assays were either done by hand or, if too fast, using a rapid chemical-quench flow 
apparatus (KinTek). Reaction products were separated using 17% acrylamide 8M urea 
sequencing gel electrophoresis.  
The resolved bands were imaged using a Typhoon TRIO (GE Healthcare) and product 
intensity quantified using ImageQuant. By plotting [Product] vs. time and using KaleidaGraph 
(Synergy Software) to generate nonlinear curvefits, kobs of nucleotide incorporation was 
determined for each [dNTP] using Equation 1 (Figure 2). 
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Figure 2: Relationship of Product Formation and Time. Each time course was fit using Equation 
1 to calculate a kobs. 
Plotting the kobs vs. [dNTP] and application of Equation 2 generated apparent kp and KD 
for incorporation of a single nucleotide on a specific gapped DNA substrate by either 
hPolλ, tPolλ, dPolλ, or hPolβ (Figure 3).  
 
Figure 3: Relationship of kobs and Nucleotide Concentration. The curve was fit using Equation 2 
to yield a kp and KD. 
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When measuring both the kp and KD of correct and incorrect nucleotide incorporation, 
fidelity was calculated using Equation 3 in order to quantify the DNA polymerase’s likelihood of 
correct incorporation. Pre-steady state kinetic assays were performed by myself, Lindsey Pack, 
and Jessica Brown, with L.P. and J.B. performing all of the assays requiring use of the rapid 
chemical-quench flow apparatus. Quantitation, data analysis, and data interpretation were shared. 
[Product] = A[1-exp(-kobst)]                                               Equation 1 
kobs = kp[dNTP]/{[dNTP]+KD}                                                         Equation 2 
Fidelity = [(kp/KD)incorrect]/[(kp/KD)correct + (kp/KD)incorrect]          Equation 3 
Results 
 The effect of gap size on DNA polymerase efficiency and fidelity:   
 a. hPolλ: We determined the kp, KD, incorporation efficiency, and fidelity of nucleotide 
incorporation by hPolλ under single turnover conditions on primer/template DNA substrates and 
DNA substrates containing gaps from 1-10 nucleotides. For example, we measured dGTP 
incorporation opposite template dC on 21-19/41mer single nucleotide gapped DNA substrate. A 
hyperbolic dependence on the observed rate constant (also signified kobs as in Equation 1) was 
observed with increasing [dGTP]. From this, the maximum rate constant of pyrophosphorolysis 
(kp) was determined to be 2.7 ± 0.1 s-1, and the apparent equilibrium dissociation constant (KD) 
for dGTP was determined to be 1.9 ±	 0.2 µM. This leads to a calculated incorporation efficiency 
of 1.4 µM-1s-1. Ratio of the incorporation efficiency with 2-10 nucleotide gaps to incorporation 
efficiency at a gap size of one was also calculated. Finally, fidelity of each misincorporation was 
calculated as described in the Methods. A complete summary of the kinetic parameters obtained 
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is provided in Appendix 1, Table 2. The following is a summary of the notable results and our 
observations: 
In brief, the presence of a downstream strand on the single nucleotide gapped DNA 
substrate increased the incorporation efficiency by 33-fold compared to primer/template DNA. 
This suggested that there is a gap size after which the downstream strand has minimal impact on 
gap-filling ability. To test this observation, 2-10 nucleotide gapped substrates were created by 
inserting bases into the DNA template, keeping the template 21-mer and downstream 19-mer 
constant. Nucleotide incorporation efficiency remained relatively constant until a gap size of 10, 
at which incorporation efficiency dropped 38-fold. This is comparable to the incorporation 
efficiency on primer/template DNA substrate, meaning that hPolλ has a maximum gap size of 9 
nucleotides for efficient nucleotide incorporation (Figure 4). 
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Figure 4. Effect of gap size on the incorporation efficiency of hPolλ. The points beyond a gap 
size of 10 indicate incorporation efficiency on primer/template DNA substrate. 
Interestingly, dCTP was the preferred misincorporation for all gap sizes. In addition, the 
efficiency of dCTP incorporation increased 7- to 41-fold as the gap size widened from 2-8 
nucleotides. dATP and dTTP, while not incorporated as efficiently as dCTP, also showed 
increased incorporation efficiency as gap size increased. This demonstrated an overall decrease 
in the fidelity of hPolλ as gap size increased.  
In summary, hPolλ maintained nucleotide incorporation efficiency on 1-9 nucleotide 
gaps while showing an overall decrease in fidelity. Low polymerase fidelity is not ideal for 
maintenance of genome integrity, making hPolλ a poor choice for LP-BER. However, we could 
not rule out hPolλ’s involvement in LP-BER without comparing it to a strong LP-BER 
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candidate. Therefore, we performed similar single-turnover kinetic studies on the gap-filling 
activity of hPolβ.  
b. hPolβ: Kinetic parameters including kp, KD, incorporation efficiency, incorporation 
efficiency ratio,  and fidelity were determined under single turnover conditions. Kinetic assays 
were performed on primer/template DNA and DNA containing 1, 2, 5, 7, and 10 nucleotide gaps. 
A complete summary of the kinetic parameters obtained is provided in Appendix 1, Table 4. 
Overall, the trends in kinetic parameters obtained were notably different than those obtained 
from hPolλ. For example, there was only a 3-fold difference in nucleotide incorporation 
efficiency between 1-nucleotide gapped and primer/template DNA substrates. Also, 
incorporation efficiency for correct and incorrect nucleotides decreased modestly for 5-7 
nucleotide gaps, then dropped 160-fold on 10 nucleotide gapped DNA. This is much larger than 
the difference between 1-nucleotide gapped and primer/template DNA substrates, suggesting an 
increase in nucleotide incorporation efficiency would occur if the gap were greater than 10 
nucleotides. Overall fidelity of hPolβ remained remarkably constant as gap size increased. These 
results indicate that hPolβ would be less efficient but more accurate than hPolλ in LP-BER 
(Figure 5). 
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Figure 5. Effect of gap size on the incorporation efficiency of hPolβ. The points at a gap size of 
“30” indicate incorporation efficiency on primer/template DNA substrate. 
The effect of hPolλ’s N-terminal domains on its ability to perform gap-filling synthesis: 
As stated in the Background, hPolλ differs structurally from hPolβ in that it has additional N-
terminal BRCT and proline-rich domains. In order to determine the effect of the N-terminal 
domains on the gap-filling ability of hPolλ, two truncated mutants of hPolλ were created. The 
first, dPolλ, lacks the BRCT domain. The second, tPolλ, lacks both the BRCT and proline-rich 
domains (Figure 6). 
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Figure 6: Sequence comparison of hPolβ, hPolλ and mutants of hPolλ. 
Single turnover kinetic studies of tPolλ and dPolλ were done on primer/template DNA 
substrate as well as on DNA substrates containing gaps of 1, 2, 5, 7, and 10 nucleotides.  A 
complete summary of the results from these assays, including calculated kp, KD, incorporation 
efficiency, efficiency ratio, and misincorporation fidelity can be found in Appendix 1, Tables 3 
and 5. The following is a summary of the notable results and our observations: 
Like hPolλ, both dPolλ and tPolλ displayed a decrease in dGTP incorporation efficiency 
on primer/template DNA in comparison to 1-nucleotide gapped DNA (28-fold and 6-fold, 
respectively). Also like hPolλ, dGTP incorporation efficiency for dPolλ and tPolλ stayed 
relatively constant on gap sizes up to 7 nucleotides and decreased dramatically on 10 nucleotide 
gapped DNA. However, both truncated versions of hPolλ maintained a higher overall fidelity 
than hPolλ as gap size increased, indicating that their presence collectively reduces the 
polymerase fidelity of full-length hPolλ by enhancing the polymerase’s propensity for 
misincorporation (Figure 7).  
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Figure 7. Effect of increasing gap size on propensity of three mutants of hPolλ and hPolβ to 
misincorporate dCTP. ‘Full lambda’ denotes hPolλ, ‘d131 lambda’ denotes dPolλ, ‘d244 
lambda’ denotes tPolλ, and beta denotes hPolβ. Fidelity was calculated using Equation 3, and 
lower numbers indicate a lower chance of misincorporation AKA a higher overall probability of 
correct nucleotide incorporation. 
A note on sequence dependence: After observing the preference of all four DNA 
polymerases to misincorporate dCTP, we hypothesized that the preference for dCTP 
misincorporation was due to the presence of a template dG immediately downstream of the 
initial template dC. We tested this hypothesis by changing the 42-mer template DNA sequence 
from 3’-CGG-5’ to 3’-CGA-5’ and 3’-CAG-5’ and performing single-turnover experiments 
similar to those described previously with hPolλ, tPolλ, dPolλ, and hPolβ. In experiments 
performed with template 3’-CAG-5’, dTTP became the preferred misincorporation. In 
experiments performed with template 3’-CGA-5’, dCTP remained the preferred 
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misincorporation, suggesting that only the adjacent nucleotide had an impact on 
misincorporation efficiency.  As observed with template 3’-CGG-5’ in which dCTP 
misincorporation efficiency increased with increasing gap size, the misincorporation efficiency 
of dTTP also increased with increasing gap size, as demonstrated by kinetic parameters obtained 
on template 47-mer containing 3’-CAT-5’ instead of 3’-CGG-5’. The full results of template 
dependence studies can be found in Appendix 1, Tables 6-9.  
Discussion 
 Though the basic BER pathway is known, the specific enzymes that perform each step 
are still unclear. For example, six mammalian DNA polymerases have been proposed to perform 
the gap-filling step of SP-BER and LP-BER, including DNA polymerases beta, delta, epsilon, 
lambda, iota, and theta(12). Characterizing the abilities of hPolλ and hPolβ to fill gaps in DNA 
added to knowledge of their biochemical function and gave insight into how they might function 
in both SP-BER and LP-BER. Key findings were as follows: 1) 9 nucleotides was the maximum 
gap size for efficient nucleotide incorporation by hPolλ, 2) as gap size increased from 2-10 
nucleotides, fidelity of hPolλ decreased, 3) the N-terminal domains of hPolλ downregulate its 
fidelity on 2-10 nucleotide gapped DNA, 4) the preferred misincorporation was based on the first 
downstream template base, 5) the fidelity of hPolβ remained similar as gap size increased, 
though incorporation efficiency decreased. The following is a more detailed discussion of these 
key findings: 
A structure-function discussion of Polλ: As mentioned, an important observation in our 
kinetic studies was that the incorporation efficiency of hPolλ remained relatively constant up to a 
gap size of 9. Crystal structures of hPolλ in complex with 2 nucleotide gapped DNA substrate 
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give insight into this ability to efficiently incorporate nucleotides; the first downstream template 
base can be bound in a “scrunching pocket”, forming a loop that allows the polymerase to 
simultaneously maintain contacts with the 3’-hydroxyl, nascent base pair, and 5’-phosphorylated 
downstream strand(13). It can be hypothesized that, until a gap size of 9 nucleotides, the loop 
becomes larger yet can still be accommodated by the polymerase. However, at a gap of 10 
nucleotides the loop is too large for contact with the 3’-hydroxyl, nascent base pair, and 5’-
phosphorylated downstream strand to all be maintained. This loss of looping ability would 
therefore account for the dramatic decrease in incorporation efficiency on 10 nucleotide gapped 
DNA. However, it should be noted that these suppositions are based on the crystal structures of 
truncated versions of hPolλ; the structure of the full-length version of hPolλ has not yet been 
solved. This lack of full-length crystal structure also complicates analysis of the structural basis 
of downregulation of fidelity by hPolλ’s N-terminal BRCT and proline-rich domains. Even so, 
based on the observation that downregulation of fidelity occurred as gap size increased it can be 
proposed that the N-terminal domains of hPolλ sterically hinder its ability to form large DNA 
loops that allow simultaneous polymerase interaction with the 3’-hydroxyl, nascent base pair, 
and 5’-phosphorylated downstream strand.  
The ability of hPolλ to ‘scrunch’ template DNA may also account for the observed 
misincorporation preference. Our kinetic analyses of sequence dependence indicated that the 
preferred misincorporation is influenced by the first downstream template base; i.e., downstream 
template dG made dCTP the preferred misincorporation. This indicates a DNA misalignment, 
which we hypothesize is due to the same scrunching pocket that allows DNA with gaps of up to 
9 nucleotides to be accommodated by hPolλ. In short, the second downstream base may instead 
occupy the scrunching pocket, stabilizing the misalignment of primer and template (Figure 1, 
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Appendix 1). This means the initial template base would be skipped, generating frameshift 
mutations. In accordance with this hypothesis, frameshift mutations have been shown to be 
characteristic of hPolλ(14). Because we also observed misincorporation preferences for dPolλ and 
tPolλ, it can be surmised that the N-terminal BRCT and proline-rich domains have minimal 
influence on stabilization of template misalignment. 
Comparison of hPolλ and hPolβ:  In the course of the above studies, hPolλ and hPolβ 
displayed discrete kinetic trends. This agrees with previous observations that, though hPolλ and 
hPolβ are homologs, they have different enzymatic properties(15,16). They share an increased 
incorporation efficiency on 1 nucleotide gapped DNA, probably due to interactions between the 
polymerase dRPase domain and the 5’-phosphorylated downstream strand. This is evidence of 
the specialization of hPolλ and hPolβ for gap-filling. However, the impact of a downstream 
strand was much less pronounced for hPolβ; a 3-fold increase rather than the 33-fold increase 
observed for hPolλ. Additionally, hPolβ was able to maintain its fidelity but lost incorporation 
efficiency as gap size, while hPolλ did not. Both enzymes showed a dramatic loss in 
incorporation efficiency on DNA containing a 10 nucleotide gap, though hPolβ was able to 
recover if the downstream strand was absent while hPolλ was not. All of this indicates that 
contacts between the polymerase dRPase domain and 5’-phosphorylated downstream strand are 
much more critical for the incorporation efficiency of hPolλ than hPolβ, perhaps because the 
contacts formed stabilize a conformation of hPolλ in which the nascent base pair is well-
positioned in the active site(17). This possibility would also indicate that hPolβ is less dependent 
on interactions between its dRPase domain and the 5’-phosphorylated downstream strand for 
optimal positioning of the nascent base pair, and that DNA containing longer gaps actually 
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hinders this catalytically competent conformation(18). As there is no structural evidence of how 
hPolβ accommodates DNA with larger gaps, further interpretation of this possibility cannot yet 
be made.   
The roles of hPolλ and hPolβ in BER: As noted previously, hPolλ and hPolβ were 
comparably competent at filling 1 nucleotide gapped DNA. This indicates the hPolλ could aptly 
perform SP-BER. Analyzing the possible involvements of hPolλ and hPolβ in LP-BER solely on 
our kinetic evidence is somewhat more complicated. Based on maintenance of polymerase 
fidelity and the cell’s goal of genomic integrity, hPolβ is better suited to LP-BER. However, 
hPolβ loses catalytic efficiency with increasing gap size. hPolλ was the opposite; maintaining 
catalytic efficiency yet losing fidelity with increasing gap size.  
Though there is evidence for hPolβ’s involvement in LP-BER(9), I also propose that there 
is sufficient evidence for the implication of hPolλ in LP-BER. Notably, BER mutational spectra 
gathered from cell line extracts show an abundance of deletion mutations. As discussed in the 
context of our sequence dependence, deletion mutations may be indicative of the catalytic 
presence of hPolλ. 
Though hPolλ and hPolβ were the only enzymes examined in this study, the involvement 
of other DNA polymerases in the gap-filling step of BER cannot be overlooked. It has been 
hypothesized previously that a combination of DNA polymerases is required for BER, especially 
LP-BER. The gap-filling activity of hPolβ and hPolλ was proposed to be limited to one 
nucleotide, either through cooperation with flap endonuclease I which would specifically 
generate a 1 nucleotide gap(20), or through cooperation with a replicative DNA polymerase which 
would take control from hPolλ or hPolβ after insertion of the initial nucleotide at the previously 
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damaged site(21,22). Though these mechanisms are hypothetical, the combination of this study 
with those conducted previously cannot exclude either hPolλ or hPolβ as potential players in SP-
BER and LP-BER. 
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Chapter 2: The Mutagenic Spectra of Cyclobutane Thymine Dimer 
Bypass by Y-family DNA Polymerases 
Background  
 As mentioned in the Introduction, UV light is one of many agents that can damage DNA. 
The most prevalent result of UV irradiation of DNA is the cis-syn cyclobutane thymine dimer 
(TT dimer, Figure 1). TT dimers stall replicative DNA polymerases, and thus must be processed 
efficiently for the cell to survive and maintain optimal function. The cell responds to TT dimers 
in one of three ways. First, dimerization can be directly reversed by a photolyase, which uses a 
radical mechanism to revert the TT dimer to undamaged, adjacent thymines. Second, the dimer 
can be processed through the nucleotide excision repair (NER) pathway, in which a section of 
25-30 nucleotides around and including the TT dimer are removed and the resulting gap filled. 
Finally, in cases where DNA replication is stalled by an unrepaired TT dimer, the cell must 
depend on specialized enzymes to bypass the lesion(24). The Y-family DNA polymerases are 
among the enzymes that can perform lesion bypass. Though they share nucleotide incorporation 
activity with replicative DNA polymerases, the Y-family enzymes have much more open active 
sites. These open active sites allow them to incorporate nucleotides opposite lesions that are not 
tolerated by the rigid active sites of replicative DNA polymerases(25). 
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Figure 1. Crystal structure of adjacent undamaged thymines (left) and cis-syn cyclobutane 
thymine dimer (right)(33). 
Interestingly, humans do not encode a photolyase and therefore depend on NER and 
lesion bypass to process TT dimers(26). Understandably, this makes proper NER and lesion 
bypass function very important. Xeroderma pigmentosum is visible proof of this importance.  XP 
is characterized by extreme sensitivity to sunlight and increased incidence of skin cancer. 
Furthermore, it is caused by defects in NER or lesion bypass enzymes. The variant form (XPV) 
is specifically due to mutation of the gene encoding human DNA polymerase eta (hPolη), a 
member of the Y-family of DNA polymerases(27). Therefore, though lesion bypass is the last 
resort of the DNA damage response, loss of the ability to bypass UV-induced photoproducts is 
damaging enough to have an observable phenotype.  
 As can be expected, hPolη is the prime candidate to perform TT dimer bypass in vivo. In 
vitro kinetic studies support this claim, demonstrating that hPolη preferentially bypasses TT 
dimers in an error-free manner. In fact, hPolη incorporates nucleotides more efficiently in the 
vicinity of a cis-syn cyclobutane thymine dimer(28), which is especially surprising due to the 20-
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30˚ distortion induced by a TT dimer(29). Recent structural studies propose an explanation for the 
fidelity and efficiency of TT dimer bypass by hPolη. Fidelity is maintained because hPolη 
stabilizes DNA containing a TT dimer into the normal B-form, promoting Watson-Crick base 
pairing. This, along with the ability of hPolη to accommodate both thymines of the dimer in its 
active site, also increases nucleotide incorporation efficiency(30). 
 Though hPolη is likely to bypass TT dimers in vivo, it is not the only member of the Y-
family of DNA polymerases (Figure 2). Humans encode 3 other Y-family members; human 
DNA polymerase kappa (hPolκ), human DNA polymerase iota (hPolι), and human Rev1 
(hRev1). As mentioned before, they all have open active sites that allow them to perform lesion 
bypass. However, this open-ness often makes lesion bypass error-prone due to loss of the steric 
requirement that normally promotes Watson-Crick base pairing. The Y-family enzymes are also 
distributive, meaning they only incorporate a few nucleotides in a single DNA-binding event.  
Previous studies indicate specialized cellular roles for each Y-family member. hPolκ is 
thought to bypass bulky minor-groove adducts and to extend from the lesion bypass products of 
other DNA polymerases(35). hPolι has been shown in vitro to bypass a variety of lesions, 
including TT dimers and 6-4 TT photoproducts(32). Finally, hRev1 is primarily a dCTP 
transferase, using one of its own amino acids as a template rather than using DNA(37). hRev1 is 
also thought to play a role in recruitment and managing of the lesion bypass process, possessing 
domains that enable it to interact with the other Y-family members(25). 
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Figure 2. Sequence alignment of several Y-family DNA polymerases. Palm domain is in red, 
finger domain in blue, thumb domain in green, little finger domain in purple, and n-digit in 
yellow. All interaction regions are otherwise identified. 
 Though hPolη and hPolι have been proven to bypass TT dimers(28,31,32), the response of 
the other Y-family DNA polymerases to TT dimers is less well known. Also unclear is how the 
lesion bypass response changes in XPV patients. Sequence data indicate an unusually high 
frequency of UV-induced mutation, the majority of which are transversions. It has been 
hypothesized that this characteristic mutation spectra is indicative of a DNA polymerase 
performing error-prone lesion bypass(27). With this information, the goals of this study were 1) to 
confirm TT dimer bypass ability by hPolη, hPolι, and the model Y-family member from 
Sulfolobus solfataricus, DNA Polymerase IV(29) (Dpo4), 2) to test the TT dimer bypass ability of 
hPolκ and hRev1, and 3) to characterize the mutagenic profile of lesion bypass by the human Y-
family DNA polymerases and Dpo4.  
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Methods 
 Materials: In addition to the reagents listed in Chapter 1, the following were purchased: 
synthetic deoxyribonucleotide 25-mer, 31-mer, 51-mer, 77-mer control, primer 17-mer, and 
reverse PCR primer 21-mer from Integrated DNA Technologies, T4 DNA ligase from New 
England BioLabs, T4 polynucleotide kinase from New England BioLabs, Taq DNA polymerase 
from Fermentas, and TOPO TA Cloning Kit from Invitrogen. A synthetic 21-mer containing a 
site-specific cyclobutane thymine dimer (21-mer TT) was acquired from Dr. John-Stephen 
Taylor at Washington University in St. Louis. Human DNA polymerase kappa (hPolκ), human 
DNA polymerase eta (hPolη), human DNA polymerase iota (hPolι), human Rev1 (hRev1), and 
Sulfolobus solfataricus DNA Polymerase IV (Dpo4) were purified as described previously(25)/ 
 Ligation of 77-mer containing a site-specific cyclobutane thymine dimer adduct: 
Synthetic deoxyribonucleotides were purified using polyacrylamide gel electrophoresis. 
Purification was shared between myself and other members of the Suo lab. Concentration of the 
purified deoxyribonucleotides was determined using UV spectroscopy at 260 nM. The 31-mer 
and 21-mer TT were 5’-phosphorylated by T4 polynucleotide kinase in the presence of 5 mM 
ATP. The 5’-phosphorylated 21-mer TT and 31mer were mixed with the 51-mer and 25-mer at a 
1.0:1.0:1.0:1.0 molar ratio. This mixture was heated to 70˚C for 8 minutes and then cooled 
slowly to promote annealing. T4 DNA ligase buffer and T4 DNA ligase were added to this 
mixture according to the manufacturer’s protocol. Ligation occurred over a 48 hour period at 
16˚C, with addition of fresh T4 DNA ligase at 24 hours. Successfully ligated 77-mer containing 
a site-specific cyclobutane thymine dimer adduct (77-mer TT) was separated from the rest of the 
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reaction mixture using 10% acrylamide 8M urea gel electrophoresis and purified as described in 
Chapter 1. I personally performed ligation of the 77-mer TT. 
 Annealing of 17/77-mer control and TT: To generate a primer/template substrate for the 
running start and short oligonucleotide sequencing assays, 17-mer was mixed with either 77-mer 
control or 77-mer TT at a 1.2:1.0 molar ratio. The mixture was heated to 95˚C for 5 minutes in 
the case of the 77-mer control and to 70˚C for 8 minutes in the case of the 77-mer TT, then 
cooled slowly to room temperature. For running start assays, a fraction of the 17-mer was 5’-
[32P]-radiolabeled as described in Chapter 1.  
 Reaction Buffer: Reactions were performed in optimized buffer “R”; 50 mM HEPES pH 
7.5 at 37˚C, 5 mM MgCl2, 50 mM NaCL, 0.1 mM EDTA, 5 mM dithiothreitol, 10% glycerol, 
and 0.1 mg/mL bovine serum albumin. As before, these concentrations are indicative of solution 
concentrations after mixing of all components 
 Running Start Assays: The running start assays were performed by mixing pre-incubated 
17/77-mer control or TT (100 nM) and Y-family DNA polymerase (100 nM) in buffer “R’” with 
a solution containing all four dNTPs (200 µM each). At various time points an aliquot was 
removed from the reaction and quenched in EDTA to a final [EDTA] of 0.37 M. Reaction 
products were separated using 17% acrylamide 8M urea gel electrophoresis and visualized using 
a Typhoon TRIO (GE Healthcare). The reactions for hPolι and hRev1 were performed 
personally by hand, and the reactions for hPolη, hPolκ, and Dpo4 by Shanen Sherrer using rapid 
chemical-quench as described in Chapter 1.  
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 Short Oligonucleotide Sequencing Assays (SOSAs): 
	  
Figure 3. Short Oligonucleotide Sequencing Assay Scheme 
 SOSAs were performed by mixing pre-incubated 17/77-mer control or TT (120 nM) and 
Y-family DNA polymerase (30 nM) in buffer “R” with a solution containing all four dNTPs (200 
µM). SOSAs were performed for all four human Y-family DNA polymerases and Dpo4; all on 
both 77-mer control and 77-mer TT. Each reaction proceeded for a time period optimized to 
maximize the amount of full-length (66-mer) product while minimizing any DNA degradation. 
To terminate the reaction, the mixture was subjected to 3 freeze-thaw cycles (-196˚C to 95˚C). 
Full-length 66-mer product was separated from template 77-mer and incompletely replicated 
deoxyribonucleotides using 10% acrylamide 8M urea gel electrophoresis. The isolated products 
were amplified using polymerase chain reaction (PCR), aided by Taq DNA polymerase, 17-mer 
forward PCR primer, and 21-mer reverse PCR primer. These primers were designed to create a 
sequencing ‘window’ of 28 bases, including 10 bases prior to the cyclobutane thymine dimer and 
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16 bases after cyclobutane thymine dimer encounter. The population of amplified DNA products 
were ligated into a pCR4-TOPO vector using a TOPO TA cloning kit (Invitrogen) and 
transformed into TOP10 E.coli (Invitrogen) according to the manufacturer’s directions. 
Individual colonies, each potentially indicative of a different full-length product, were picked 
and their plasmids sequenced (Genewiz, Inc). SOSA duties were shared between myself and 
Shanen Sherrer. 
Results 
 Running start assays: While performing running start assays of human Y-family DNA 
polymerase and Dpo4 bypass of cyclobutane thymine dimers, we had two primary goals. First, 
we intended to confirm that TT dimer bypass is possible for hPolη, hPolι, and Dpo4. The 
abilities of Dpo4 and hPolη to bypass TT dimers have been studied previously via running start 
assays(31), though not under consistent reaction conditions or the conditions used in our short 
oligonucleotide sequencing assays. The ability of hPolι to incorporate nucleotides opposite a TT 
dimer was previously observed by steady state kinetic assays(32), but not running start assays. It is 
instructive to perform running start assays in addition to kinetic assays of nucleotide 
incorporation at the lesion in order to observe polymerase behavior before, after, and at the 
lesion. The second aim of our running start assays was to test the ability of hPolκ and hRev1 to 
perform TT dimer bypass, which is largely unstudied.  
 We observed that all DNA polymerases studied were able to bypass a cyclobutane 
thymine dimer to varying degrees. This ability was indicated by the presence of product past the 
site of the lesion on 17/77-mer primer/template DNA containing a site-specific TT dimer. For 
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each running start assay performed on 17/77mer-TT DNA substrate, a similar running assay was 
performed on 17/77-mer control DNA substrate for comparison.  
DNA substrates for running start assays and SOSAs 
17/77-mer control  
	  
17/77-mer TT 
 
Table 1. Annealed 17/77-mers for running start assays and SOSAs. The position of the lesion is 
highlighted in blue with the dimer indicated by a ^.  
In general, we looked for pause sites on both control and damaged DNA substrates, 
indicative of polymerase stalling. The following is a brief relation of the pausing patterns of each 
enzyme: 
 i. hPolη: On control DNA, hPolη exhibited no significant pausing. On damaged DNA, 
several pause sites were observed. Several pause sites were areas of sequence redundancy 
(positions 20, 21, 24). hPolη also stalled at position 27, or upon insertion opposite T2 of the TT 
dimer. No further pausing was observed (Appendix 2, Figure 1). 
 ii. hPolκ: On control DNA, hPolκ exhibited no significant pausing. On damaged DNA, 
several pause sites were observed. As with hPolη, hPolκ stalled at areas of sequence redundancy 
(positions 20 and 22). The running start assay for hPolκ also displayed product accumulation at 
positions 26 and 27, indicating stalling upon insertion opposite both dTs of the TT dimer. No 
further pausing was observed (Appendix 2, Figure 2). 
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 iii. hPolι: Pausing was observed in similar locations on both control and damaged DNA. 
Speciifcally, strong pausing occurred in areas of sequence redundancy (positions 18, 21, 22). 
Cyclic pausing was also observed downstream of the site of the TT dimer at positions 32, 34, 37, 
and ~42. The difference in pausing observed between control and damaged DNA is solely 
around the site of the TT dimer, specifically in the amplified product accumulation at positions 
26 and 28 that is indicative of stalling upon insertion opposite the first dT of the TT dimer and 
upon extension from the TT dimer (Appendix 2, Figure 3).  
 iv. hRev1: Pausing was observed on both the control and damaged DNA templates. As 
with hPolι, these were often areas of sequence redundancy (position 22). There was also 
significant pausing at positions 24, 25, 26, and slightly at 27 on the control substrate and 
positions 25, 26, 27, and 28 on the damaged substrate. On the damaged substrate this indicates 
pausing upon insertion opposite each dT of the TT dimer, extension from the lesion, and 
immediately prior to lesion encounter. On the control substrate this indicates pausing opposite 
template purines dA and dG and opposite both dTs of a doublet dT (Appendix 2, Figure 4). 
 v. Dpo4: On control DNA, Dpo4 exhibited no significant pausing. On damaged DNA, 
several pause sites were observed. As with the other DNA polymerases, sequence redundancy 
caused polymerase stalling (positions 18, 20). Dpo4 also stalled upon nucleotide incorporation 
opposite T1 of the TT dimer (Appendix 2, Figure 5). 
The running start assays also allowed us to extract quantitative data about the relative TT 
dimer bypass efficiencies of the human Y-family DNA polymerases and Dpo4. Specifically, we 
calculated %bypass of each dT of the TT dimer and % bypass of the complete lesion at each time 
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point using Equation 4. By plotting the % bypass over time, we estimated a t50 of T1 bypass, T2 
bypass, and whole lesion bypass for each enzyme studied.  
% bypass = (bypass events/encounter events) x 100%          Equation 4 
Note: T1 bypass events were found by summing the concentration of all intermediate and full length products of size 
>27 base pairs. T2 bypass and whole lesion bypass events encompassed all bands >28 base pairs. T1 and whole lesion encounter 
events encompassed all bands >26 base pairs, T2 encounter events encompassed all bands >27 base pairs. 
 Based on t50 bypass values, hPolη was the most efficient at bypass of T1, T2, and the 
whole lesion, followed by Dpo4, hPolκ, hPolι, and hRev1 (Table 2). Though hRev1 displayed a 
t50 bypass for both T1 and T2, it did not bypass 50% of the whole TT dimer in the time surveyed 
(4 hours). This is possible because, for bypass of T1 and T2, only encounter events for that 
particular nucleotide were accounted for. At each time point there were fewer encounter events 
for T2 than T1, especially due to polymerase stalling at T1. Additionally, t50 of whole lesion 
bypass takes into account the encounter events for T1 and the bypass events for T2, and therefore 
is a longer estimated time. The same reasoning can be carried over to all Y-family DNA 
polymerases studied, though only hRev1 did not reach a t50 of whole lesion bypass.  
Enzyme t50 T1 bypass (s) t50 T2 bypass (s) t50 lesion bypass (s) 
hPolη 0.77 0.79 16.79 
hPolκ 14.6 33.5 304 
hPolι 70 297 1586 
hRev1 5229 7789 not observed 
Dpo4 0.8 23.5 52.1 
Table 2. A summary of estimated t50 of T1, T2, and whole lesion bypass by Y-family DNA 
polymerases.  
 Short oligonucleotide sequencing assays: As stated previously, our goal in performing 
SOSAs was to observe the mutagenic spectra of TT dimer lesion bypass. Specifically, we 
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observed deletion, substitution, and insertion mutations within a 28 nucleotide sequencing 
window that encompasses, pre-lesion, lesion, and post-lesion events. This method generates data 
that is complementary to kinetic studies though broader in scope. It should be noted that these 
assays are still in progress, thus the data presented herein is preliminary. For each enzyme, 
SOSAs were performed on a 77-mer TT DNA substrate in order to observe mutagenic preference 
opposite the lesion. SOSAs were also performed on a 77-mer control DNA substrate so that the 
effect of the TT dimer on upstream and downstream incorporations could be evaluated. The 
following is a summary of the results for each enzyme: 
 i. hPolη: 11 colonies have been sequenced for control DNA and data collection is still in 
process for damaged DNA. Control sequences indicate a random spectrum of mutations with no 
notable increase in mutagenicity at any spot on the template (Appendix 2, Figure 6). 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure 4. The mutagenic spectra of polymerization by hPolη on 77-mer control DNA. The 
relevant template sequence is denoted below the chart. 
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 ii. hPolκ: 25 colonies have been sequenced for control DNA and 14 for damaged DNA. 
At the TT dimer, hPolκ bypassed accurately, made double base deletions, or made double base 
substitutions. Accurate bypass accounted for 21.4% of sequences, double base deletions for 
35.7%, and double base substitutions for 42.9%. Substitutions observed at the lesion were all 
insertion of T opposite T1 and insertion of either G or C opposite T2. Random mutations were 
observed upstream and downstream of the lesion, with a notable increase 4 and 5 bases 
downstream of the lesion (positions 32 and 33). A random spectrum of mutation was also 
observed on control DNA, with no particular increase in mutagenicity at any spot on the template 
(Appendix 2, Figures 7 and 8). 
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Figure 5. The mutagenic spectra of polymerization by hPolκ on A. 77-mer control DNA, B. 77-
mer TT DNA. The relevant template sequences are denoted below the chart, as well as position 
from the lesion. 
iii. hPolι: 6 colonies were sequenced for control DNA and 21 colonies were sequenced 
for damaged DNA. At the TT dimer, hPolι made a double base deletion or a single base 
substitution. Double base deletions accounted for 95.2% of sequences, and single base 
substitutions (T opposite T1) accounted for 4.8% of sequences. Random mutations were 
observed both upstream and downstream of the lesion. Interestingly, the mutagenic events were 
roughly cyclic, i.e., there was an increase in mutations approximately every 4-5 nucleotides 
before and after the TT dimer. A random spectrum of mutations was observed for control 77-
mer, with the only notable increases being at positions 27, 28, and 44 of the DNA template 
(Appendix 2, Figures 9 and 10).   
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Figure 6. The mutagenic spectra of polymerization by hPolι on A. 77-mer control DNA, B. 77-
mer TT DNA. The relevant template sequences are denoted below the chart, as well as the 
position from the lesion. 
 iv. hRev1: Data collection is still in process for hRev1.  
 v. Dpo4: 65 colonies were sequenced for control DNA and 28 colonies were sequenced 
for damaged DNA. At the TT dimer, Dpo4 bypassed accurately, made a double base deletion, 
made a single base substitution, or performed a combination substitution-deletion. Accurate 
bypass accounts for 32.1% of sequences, double base deletion for 46.4% of sequences, single 
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base substitution for 17.9% of sequences, and combination substitution-deletion for 3.6% of 
sequences. Notably, all single base substitutions were incorporation of C opposite T2 of the TT 
dimer. Remarkably few mutations were observed on 77-mer control DNA template; only 4 
substitutions out of 65 sequences (Appendix 2, Figures 11 and 12).  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	    
 
Figure 7. The mutagenic spectra of polymerization by Dpo4 on A. 77-mer control DNA, B. 77-
mer TT DNA. The relevant template sequences are denoted below the chart. 
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 After initial sequence analysis, we also found the total error frequency of each Y-family 
DNA polymerase on both control and damaged templates using Equation 5 (Table 3).  
Enzyme Total Error 
Frequency  
(77-mer control) 
Total Error 
Frequency  
(77-mer TT) 
Total Error 
Frequency except 
TT dimer site 
(77-mer TT) 
hPolκ  5.6 x 10-2 1.5 x 10-1 1.0 x 10-1 
hPolη  8.4 x 10-2 -- -- 
hPolι  1.4 x 10-1 1.7 x 10-1 1.0 x 10-1 
hRev1 -- -- -- 
Dpo4 2 x 10-3 6.1 x 10-2 2 x 10-2 
Table 3. The total error frequencies on control and damaged DNA, calculated using Equation 5. 
Total error frequency = total # mutations / # bases sequenced         Equation 5 
 In summary, efficiency of TT dimer bypass by the Y-family DNA polymerases studied is 
as follows: hPolη > Dpo4 > hPolκ > hPolι > hRev1. Dpo4 was least error prone on control 
DNA, followed by hPolκ, hPolη, and hPolι. Thus far, Dpo4 is also least error prone on damaged 
DNA, followed by hPolκ and hPolι. hPolη remains to be sequenced for 77-mer TT DNA 
substrate. Polymerase stalling was observed at both the TT dimer and in areas of DNA 
redundancy (triplet dG, doublet dT) for all Y-family DNA polymerases studied. DNA 
redundancy has been observed to cause polymerase stalling in other experiments performed in 
our lab, and did not correlate with areas of increased error.  
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Discussion 
 Cyclobutane thymine dimers are the most common UV-induced DNA lesions. They are 
problematic because they present a strong block to replicative DNA polymerases and also 
promote mutation and cancer formation. In humans, lesion bypass is an important process by 
which cyclobutane thymine dimers (TT dimers) are tolerated. The Y-family of DNA 
polymerases is specialized for lesion bypass and, in humans, the Y-family DNA polymerase eta 
(hPolη) has been strongly implicated in TT dimer bypass(24). In fact, the disease xeroderma 
pigmentosum variant (XPV), which is characterized by increased incidence of UV-induced skin 
cancer, is caused by mutations in the gene encoding hPolη. XPV cell lines indicate a 
characteristic spectrum of transversion mutations, which may be due to changes in the lesion 
bypass response in the absence of functional hPolη(27). This study profiles bypass of a TT dimer 
by all human Y-family DNA polymerases as well as the model Y-family member from 
Sulfolobus solfataricus, DNA Polymerase IV (Dpo4). We employed running start assays and 
short oligonucleotide sequencing assays for a thorough characterization of the efficiency and 
mutagenicity of lesion bypass by each DNA polymerase. In accordance with previous studies of 
the Y-family DNA polymerases, our results suggest that though the Y-family members share 
lesion bypass ability, they utilize different mechanisms to process DNA lesions(25). Below, I will 
discuss our current results in light of previous studies of TT dimer bypass and in light of current 
mechanistic and structural knowledge of each enzyme.  
 i. hPolη: As mentioned previously, there is strong support for the theory that hPolη is the 
major DNA polymerase responsible for error-free TT dimer bypass in vivo. The recently 
published crystal structure of hPolη in complex with DNA containing a TT dimer and incoming 
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dAMPNPP gives insight into the molecular basis of hPolη’s TT dimer bypass ability. hPolη 
effectively stabilizes both thymines of the dimer in a structure akin to that of undamaged DNA 
by holding both in its active site at once. This allows for normal Watson-Crick base pairing and 
relatively error-free lesion bypass(31). The specialization of hPolη for TT dimer bypass is further 
indicated by its lowered error frequency on damaged DNA, indicating that a TT dimer may be a 
better substrate for hPolη than two undamaged thymines(28).  
 It is interesting that, though hPolη can accommodate both thymines of a TT dimer in its 
active site at once, nucleotide incorporation efficiency at both thymines is not equal. We 
observed slight stalling upon incorporation opposite T1 of the lesion, but much more pronounced 
stalling upon incorporation opposite T2. Fortunately, the ternary crystal structure of yeast DNA 
polymerase eta (yPolη) may explain this phenomenon. In structures comparing damaged and 
undamaged DNA, T1 was in almost identical positions. In contrast, T2 shifted subtly in reference 
to nearby amino acid side chains. Though subtle, this shift was proposed by the authors to 
account for slight stalling with no observed change in error frequency(33). We observed slight 
stalling, but change in error frequency remains to be confirmed by our sequencing data. So far, 
sequencing data from control DNA substrate indicate a total error frequency of 8.4 x 10-2, which 
is in accord with previous studies of the error frequency of hPolη on undamaged DNA. Based on 
previous studies of hPolη, we expect the total error frequency to be lower in the vicinity of the 
lesion than in the corresponding area of control DNA.  
 ii. hPolκ: hPolκ is primarily implicated in bypass of bulky minor groove adducts and in 
extension from DNA lesions(4). We found that hPolκ was capable of TT dimer bypass, with 
polymerase efficiency and fidelity second only to hPolη amongst the human Y-family DNA 
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polymerases. Previous studies indicate that it has a higher fidelity than that of hPolη, usually 10-
3-10-4 on undamaged DNA. We observed a total error frequency of 5.6 x 10-2, which is 56- to 
560-fold higher than the previous calculations(34). This discrepancy can be neatly resolved by the 
ability of hPolκ to extend mismatched primer termini 10-100x more efficiently than matched 
primer termini. This would lead to mutations being extended more frequently and therefore more 
frequently observed in our full-length products.    
The propensity to extend mismatches may also be critical to the mechanism by which 
hPolκ was able to perform TT dimer bypass. Only 22% of the sequences collected were results 
of accurate lesion bypass; the other 78% were the result of hPolκ extending mismatched primer 
termini due to substitution or deletion mutations. Unfortunately, hPolκ has not been extensively 
studied in terms of TT dimer bypass, so its exact mechanism of lesion accommodation and 
nucleotide incorporation is unclear.  
As the Y-family DNA polymerase with the highest fidelity, hPolκ also has the most 
restrictive active site. The running start assay indicates pausing upon incorporation opposite both 
thymines of the dimer, indicating that hPolκ may only able to hold one template base in its active 
site at once. Pausing is much stronger upon incorporation of the first dT. This can be explained 
by the only other study of hPolκ’s TT dimer bypass activity; a recent crystal structure of hPolκ 
incorporating dATP opposite T2 of the lesion. hPolκ is able to hold T2 in the same positioning as 
an undamaged dT. The authors did not crystallize nucleotide incorporation opposite T1, but 
theorized that the active site of hPolκ is too restrictive to easily accommodate T1(35). If true, 
these hypotheses would explain the pausing pattern observed in our running start assay. 
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There are two main hypotheses regarding the role of hPolκ in TT dimer bypass. The first 
is that it is not involved at all. The cornerstone of this hypothesis is that hPolη is known to 
accommodate both bases of the TT dimer in its active site and to incorporate nucleotides 
opposite the lesion efficiently and correctly(28). The binding affinity of hPolη drops 3-4 
nucleotides after the lesion, promoting dissociation from DNA and facilitating the switch back to 
a replicative DNA polymerase. Therefore, a specialized polymerase to extend from the lesion 
would not be needed. The second hypothesis made by Vasquez-del Carpio et al. is that hPolη 
only inserts dATP opposite T1 of the dimer, leaving hPolκ to incorporate dATP opposite T2 of 
the lesion and then extend from the lesion(35). Our study indicates some pausing by hPolη after 
incorporation opposite T1, indicating that hPolκ could be involved. In addition, hPolη and hPolκ 
are both distributive and could feasibly compete for nucleotide incorporation.  
 iii. hPolι: In this study, we observed that hPolι is able to bypass TT dimers with low 
bypass efficiency as well as a high rate of polymerase error. The calculated total error frequency 
of 1.4 x 10-1 on undamaged DNA is in accordance with previous studies of hPolι and likely due 
to its unusual method of base pairing that varies with template base. For example, though hPolι 
prefers to form correct Watson-Crick base pairs opposite template dA, it prefers to form wobble 
pairs opposite template dT. This leads to slight preference of dGTP incorporation over dATP 
incorporation(36). We did not observe that extreme of a preference in our mutagenic spectra, 
though it should be noted that 36% of mutations opposite template dT were the insertion or 
substitution of dGTP.  
Previous steady state kinetic studies indicate a complex mechanism of TT dimer bypass 
for hPolι. It was observed that hPolι prefers to incorporate dT opposite T1 of the lesion, with 
	   44	  
secondary preference for dA incorporation. After incorporation opposite T1, dA is extended 
more easily, and the most common nucleotide to be inserted opposite T2 is dGTP. However, they 
then observe that AG is not easily extended from(32). Interestingly, this could account for the 
heavy pausing upon extension from the TT dimer observed in our running start assay. It could 
also explain why the sequences of TT dimer bypass products collected displayed mostly 
deletions at the site of the lesion, as the previous GC base pair may be more easily extended. 
Interestingly, the strong pausing and complex interplay of incorporation and extension ability 
exhibited by hPolι suggests that it could be aided in the cell by a polymerase such as hPolκ, 
which preferentially extends from mismatched primer termini. 
 Though hPolι has a low bypass efficiency and overall fidelity, it is currently the prime 
candidate to perform photoproduct lesion bypass in the absence of functional hPolη. The reasons 
for this hypothesis are as follows: 1) XPV patients exhibit 10% of normal lesion bypass 
activity(32), 2) XPV cell line sequences indicate a high rate of dT to dC transversions(27), and 3) 
hPolι is a paralog of hPolη and therefore may be recruited similarly(32). Our results are in accord 
with this hypothesis. The loss of bypass ability can be accounted for by the low catalytic and TT 
dimer bypass efficiency of hPolι, and the dT to dC transversions can be accounted for by the 
preference of hPolι to insert dGTP opposite dT, which would lead to a dC in place of dT upon 
the next round of DNA replication.  
 iv. hRev1: Though hRev1 is in the Y-family of DNA polymerases, it is technically a 
dCMP transferase. Instead of determining the incoming nucleotide using a template base, hRev1 
uses one of its arginine side chains to pair with an incoming dCTP. Due to this extreme selection 
bias, it preferentially incorporates dCTP opposite dG, dA, dC, and dT. Therefore, it has been 
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previously proposed that hRev1’s lesion bypass ability is tightly limited to dG adducts(37). 
Though we had the surprising result that hRev1 had marginal TT dimer bypass ability, it did not 
reach a t50 bypass in our running start assay. It was also notably inefficient at replicating control 
DNA, indicative of a low overall incorporation efficiency. Therefore, we believe it is not 
catalytically involved in TT dimer bypass under normal or hPolη-deficient conditions. Due to 
extremely low polymerization efficiency and known dCMP transferase activity, we may not 
sequence hRev1 bypass products. With our method, the sequences collected would likely be 
results of extreme selection bias.  
 Though its catalytic activity is limited, hRev1 is still thought to have an important role in 
lesion bypass. As alluded to in the Background, hRev1 is thought to mediate polymerase 
switching during lesion bypass. This proposal is due to the ability to interact with proliferating 
cell nuclear antigen (PCNA), ubiquitinated proteins, and human DNA polymerases eta, kappa, 
iota, and zeta(38). In short, hRev1 has a unique role in the cell that deserves further study, but it is 
not catalytically relevant when studying TT dimer bypass. 
 v. Dpo4: The archaeon from which Dpo4 originates, Sulfolobus solfataricus, is a 
hyperthermophile. In this extreme environment, the DNA of S. solfataricus faces a high level of 
stress. Thus far, Dpo4 is the only DNA polymerase isolated from this extremophile capable of 
lesion bypass. This implies that Dpo4 must be proficient at bypassing a wide variety of DNA 
lesions in an error-free manner in order for S. solfataricus to maintain genome integrity and 
proper cellular functions. Indeed, Dpo4 was efficient at TT dimer bypass and displayed a 
relatively low rate of mutation on both control and damaged DNA. Its total error frequency on 
undamaged DNA was 2x10-3, which is in accord with the calculated fidelity of Dpo4 from 
kinetic studies. The total error frequency rose to 6.1 x10-2 on damaged DNA, though this is still 
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lower than the total error frequency on damaged DNA of any human Y-family DNA 
polymerases.  
A heavy pause before nucleotide incorporation opposite the first dT of the TT dimer 
indicated polymerase stalling. Based on previous steady state kinetic studies of Dpo4, we 
hypothesize that this is due to the inability of the enzyme to “flip out” T2 of the lesion as it 
brings T1 into its active site as it would do during normal nucleotide incorporation(31). We 
hypothesize that this stalling is due to a slow accommodation step in which Dpo4 brings both 
thymines of the dimer into its active site. This hypothesis is in accordance with the ternary 
crystal structure of Dpo4, DNA containing a TT dimer, and incoming ddADP, in which Dpo4 
did indeed accommodate both thymines in its active site at once(39). Intriguingly, we observed 
that this strong pausing point did not correlate with an increase in polymerase error or lowered 
incorporation efficiency at T1 of the TT dimer. Instead, incorporation occurred with similar 
fidelity and efficiency at both dTs of the TT dimer. This is in accord with previous steady state 
kinetic studies of incorporation at the lesion(31).  
It should be noted that the aforementioned steady state kinetic and crystallographic 
studies disagree on their interpretations of the mechanism by which Dpo4 bypasses a TT dimer – 
not only in the details mentioned above but also in the absence or presence of a translocation step 
and in the type of base pairing (Watson-Crick or Hoogsteen) used to incorporate dATP opposite 
the lesion. Our investigation supports a slow TT dimer accommodation step in which both 
thymines are brought into the active site of Dpo4, followed by relatively equal efficiency and 
fidelity of nucleotide incorporation opposite the lesion. However, further clarification of Dpo4’s 
TT dimer bypass mechanism is necessary to resolve the dispute between steady state kinetic and 
structural studies. 
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vi. The effect of DNA structure on DNA polymerase fidelity: As mentioned above, the 
presence of a TT dimer had both local and global effects on polymerization fidelity. Local effects 
were noticed upon insertion opposite both dTs of the TT dimer and upon the subsequent 
extension step from the TT dimer. Global effects were noticed on an overall increase in error 
frequency on the damaged DNA substrate. The crystal structure of cyclobutane thymine dimer-
containing DNA may explain this increase in total error frequency; the presence of a TT dimer 
bends the helix by 30˚ towards the major groove and unwinds the helix by 9˚(29). The mutagenic 
spectra of TT dimer bypass by hPolκ and hPolι show an interesting increase in mutation at 
roughly 4-5 nucleotides after the lesion. The effect is cyclic for hPolι, with an increase in error 
frequency every 4-5 nucleotides through the entire sequencing window. Similar downstream 
effects have been observed for other lesions(40), and we hypothesize that this may be due to an 
increase DNA structural distortion at each turn of the double helix away from the lesion.  
 In summary, our study provided further evidence that hPolη is the DNA polymerase that 
bypasses cis-syn cyclobutane thymine dimers in vivo due to its high efficiency of lesion bypass. 
We hope further confirmation will be provided by the sequences of TT dimer lesion bypass 
products. We observed that hRev1 is not catalytically relevant for TT dimer bypass, though other 
studies have suggested its role in facilitating polymerase switching for lesion bypass. Our study 
also supports the hypothesis that hPolι is the DNA polymerase that substitutes for hPolη in 
humans with XPV because it has decreased lesion bypass efficiency and creates the same 
mutations observed in XPV cell lines. Finally, we observed the bias of hPolκ for extension of 
mismatched primer termini by comparing our results to kinetic studies of fidelity, which has 
application to the proposed role of hPolκ in extending from initial lesion bypass products. 
	   48	  
Overall, however, I must reiterate that the data presented herein is preliminary and that further 
sequences must be collected to verify the statistical validity of our results.  
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Chapter 3: The Mutagenic Spectra of Cisplatin-dGpG Bypass by Y-
family DNA Polymerases 
Background 
 Most damage to cellular DNA is unintentional; a product of the environment that the cell 
is exposed to. In the case of select chemotherapeutic agents, however, DNA damage is quite 
intentional. Cis-diamminedichloroplatinum(II), also known as cisplatin, is a perfect example. 
Cisplatin is a chemotherapeutic agent used to treat testicular, ovarian, head, neck, and non-small 
cell lung cancers. It is an effective anti-cancer agent because it hinders a cell’s ability to divide, 
consequently slowing tumor growth. Cisplatin hinders cell division by creating lesions in DNA 
that obstruct DNA replication(42). The most common lesion created by cisplatin treatment is the 
intrastrand crosslinking of adjacent guanines; often termed a ‘cisplatin-dGpG’ adduct(42).  
	  
Figure	  1.	  Comparative	  crystal	  structures	  of	  undamaged	  DNA	  and	  DNA	  containing	  a	  cisplatin-­‐dGpG	  adduct. 
	   50	  
 Unfortunately, a major limitation of cisplatin therapy is the prevalence of drug resistance. 
In vivo studies of this dilemma led to the hypothesis that lesion bypass is the mechanism of drug 
resistance(43), and it is a logical assumption to propose that stalled DNA replication would be 
responded to in the same way whether the lesion is intentionally or unintentionally introduced. It 
is therefore important to study cisplatin-dGpG lesion bypass in order to test this hypothesis.  
Among the primary candidates to perform cisplatin-dGpG lesion bypass are the Y-family 
DNA polymerases(42). Previous studies have focused on hPolη(43-46). In vitro kinetic studies 
indicate that hPolη preferentially bypasses cisplatin-dGpG lesions in an error-free manner, 
inserting dCTP opposite both guanines of the adduct. hPolη-deficient (XPV) cell lines also show 
increased sensitivity to cisplatin; a sensitivity that decreases when the cells are complemented 
with wild-type hPolη(43). Though these studies strongly support hPolη’s role in cisplatin-dGpG 
bypass, the ability of other Y-family DNA polymerases to bypass cisplatin-dGpG adducts is 
largely unknown. Therefore, our goals were 1) to confirm cisplatin-dGpG bypass ability by 
hPolη, 2) to test the cisplatin-dGpG bypass ability of hPolκ, hPolι, and hRev1, and 3) to 
characterize the mutagenic profile of lesion bypass by the human Y-family DNA polymerases 
and the model Y-family member from Sulfolobus solfataricus, DNA Polymerase IV (Dpo4).     
Methods 
 Materials: In addition to the reagents mentioned in Chapters 1 and 2, the following were 
purchased: synthetic deoxyribonucleotide overhang 15-mer with 5’-monophosphate (15-mer P), 
primer 15-mer, reverse primer 15-mer, 24-mer, 18-mer, 29-mer, 47-mer, and 54-mer control 
from Integrated DNA Technologies. A 12-mer containing a site-specific cisplatin-dGpG adduct 
was synthesized previously.  
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 Ligation of 54-mer containing a site-specific cisplatin-dGpG adduct for running start 
assays: All deoxyribonucleotides received from Integrated DNA Technologies were purified 
using polyacrylamide gel electrophoresis as in previous chapters. An 18-mer and a 12-mer 
containing a site-specific cisplatin-dGpG adduct (12-mer CISP) were 5’-phosphorylated as 
described in Chapter 2. The phosphorylated 18-mer and 12-mer CISP were mixed with 47-mer 
and 24-mer in a 1.0:1.0:1.0:1.0 molar ratio. Annealing, ligation, and purification of 54-mer CISP 
were performed in the same manner as the ligation of the 77-mer TT in Chapter 2.  
 Running Start Assays: For running start assays, primer 15-mer was annealed to 54-mers 
control and CISP by heating to 95˚C and cooling slowly to room temperature. Running start 
assays were performed under the same conditions as in Chapter 2. 
 Ligation of 69-mers control and CISP for short oligonucleotide sequencing assays: In 
order to separate template DNA from product DNA on a sequencing gel, 69-mers control and 
CISP were synthesized by adding an overhanging 15-mer to the 54-mers control and CISP. 15-
mer P, 54-mer control or CISP, and scaffold 29-mer were mixed at a 1.0:1.0:1.0 molar ratio, 
heated to 95˚C, and cooled slowly to promote annealing. T4 DNA ligase (NEB) was added 
according to the manufacturer’s directions, and ligation proceeded for 3 hours at 22˚C. The 69-
mers control and CISP were purified as described in Chapter 2. Ligation and DNA purification 
duties were shared between myself and other members of the lab. 
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 Short Oligonucleotide Sequencing Assays:  
	  
Figure 2. Scheme for short oligonucleotide sequencing assay for cisplatin-dGpG bypass. 
For SOSAs, primer 15-mer was annealed to 69-mers control and CISP in the same manner as the 
15/54-mers. SOSAs were performed by mixing pre-incubated 15/69-mer control or CISP (120 
nM) and Y-family DNA polymerase (30 nM) in buffer “R” with a solution containing all four 
dNTPs (200 µM). SOSAs were performed for all four human Y-family DNA polymerases and 
Dpo4; all on both 69-mer control and 69-mer TT. Each reaction proceeded for a time period 
optimized to maximize the amount of full-length (54-mer) product while minimizing any DNA 
degradation. To terminate the reaction, the mixture was subjected to 3 freeze-thaw cycles (-
196˚C to 95˚C). Full-length 54-mer product was separated from template 69-mer and 
incompletely replicated deoxyribonucleotides using 10% acrylamide 8M urea gel 
electrophoresis. The isolated products were amplified using polymerase achain reaction (PCR), 
aided by Taq DNA polymerase, 15-mer forward PCR primer, and 15-mer reverse PCR primer. 
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These primers were designed to create a sequencing ‘window’ of 24 bases, including 8 bases 
prior to the cisplatin-dGpG and 14 bases after cisplatin-dGpG encounter. The population of 
amplified DNA products were ligated into a pCR4-TOPO vector using a TOPO TA cloning kit 
(Invitrogen) and transformed into TOP10 E.coli (Invitrogen) according to the manufacturer’s 
directions. Individual colonies (each potentially indicative of a different full-length product) 
were picked and their plasmids sequenced (Genewiz, Inc). I personally performed two SOSAs 
and optimization assays for several others; the other complete SOSAs were performed 
previously.  
Results 
Running start assays: While performing running start assays of human Y-family DNA 
polymerase and Dpo4 bypass of cisplatin-dGpG adducts, we had two primary goals. First, we 
intended to confirm that cisplatin-dGpG bypass is possible for hPolη and Dpo4. Second, we 
aimed to test the ability of hPolι, hPolκ, and hRev1 to bypass cisplatin-dGpG adducts, which 
was largely unstudied. It was especially beneficial to confirm the ability of hPolη and Dpo4 to 
perform cisplatin-dGpG bypass under our reaction conditions such that we have a basis for 
comparison for the untested DNA polymerases. 
 We observed that all DNA polymerases studied were able to bypass a cisplatin-dGpG 
adduct to various degrees, as indicated by product past the site of the lesion on the 15/69-mer 
primer/template DNA containing a site-specific cisplatin-dGpG lesion. For each running start 
assay performed on 15/69mer-CISP DNA substrate, a similar running assay was performed on 
15/69-mer control DNA substrate for comparison.  
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DNA substrates for running start assays and SOSAs 
15/69-mer control  
	  
15/69-mer CISP 
 
Table 1. Annealed 15/69-mers for running start assays and SOSAs. The position of the lesion is 
highlighted in red.  
In general, we looked for pause sites on both control and damaged DNA substrates, 
indicative of polymerase stalling. The following is a brief relation of our observations from the 
running start assays:  
i. hPolη:  On control DNA, no significant pausing was observed. On DNA containing a 
cisplatin-dGpG adduct, heavy pausing was noticed at positions 25 and 26, indicating polymerase 
stalling upon extension from the cisplatin-dGpG adduct and the subsequent nucleotide 
incorporation (Appendix 3, Figure 1). We observed lesion bypass products (25-mer) after 2 
seconds, and a significant amount of full length product on damaged after 10 seconds. In 
comparison, we observed 25-mer after 1 second and full length product after 5 seconds on 
control DNA. 
ii. hPolκ: On control and damaged DNA, pausing was observed at positions 16, 20, and 
21. All were areas of sequence redundancy (doublet dG, doublet dCdT), which was previously 
noted to cause polymerase stalling in Chapter 2. hPolκ paused strongly at position 23 on the 69-
mer CISP, indicative of polymerase stalling upon incorporation opposite the first dG of the 
cisplatin adduct. We observed full-length products on damaged DNA after 90 seconds and on 
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control DNA after 60 seconds. A band indicating lesion bypass product was not obvious on 
damaged DNA, though full-length product at 90 seconds indicates that the lesion must have been 
bypassed previously (Appendix 3, Figure 2).  
iii. hPolι: Running start assays have not yet been performed for hPolι due to material 
constraints. 
iv. hRev1: Running start assays have not yet been performed for hRev1 due to material 
constraints. 
v. Dpo4: On control DNA, no significant pausing was observed. On DNA containing the 
cisplatin adduct, pausing was noticed at positions 23 and 24. Pausing at position 24 was far 
stronger, indicative of polymerase stalling upon incorporation opposite the second dG of the 
cisplatin adduct. We observed lesion bypass products (25-mer) after 4 seconds and full-length 
product after 60 seconds on damaged DNA. In comparison, we observed 25-mer after 2 seconds 
and full-length product after 30 seconds on control DNA (Appendix 3, Figure 3). 
 Short oligonucleotide sequencing assays: Our goals in performing SOSAs were to profile 
the mutagenic spectra of cisplatin-dGpG lesion bypass by the human Y-family DNA 
polymerases and Dpo4. This is instructive because many studies of lesion bypass are only 
concerned with error frequency at the lesion, and do not study mutagenic events upstream and 
downstream of the lesion. As we have noticed in previous studies, the presence of a lesion can 
effect upstream and downstream nucleotide incorporation(40). The following is a summary of our 
current results from SOSAs: 
i. hPolη: Sequence collection is still in progress for hPolη. 
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ii. hPolκ: On control DNA, hPolκ exhibited a random spectra of mutations except for a 
notable increase in deletions at position 22, which corresponds to the second dC of a doublet dC. 
The presence of a cisplatin-dGpG adduct had a dramatic effect on the error frequency of hPolκ, 
with a sharp increase in deletions for a 9-nucleotide region around the lesion (Appendix 3, 
Figures 4 and 5). 
A.  
B.  
Figure 3. Mutagenic spectra of polymerization by hPolκ on A. 69-mer control DNA and B. 69-
mer CISP DNA. The relevant template sequences are denoted below the charts. 
	   57	  
iii. hPolι: Sequences have not yet been collected for hPolι. 
iv. hRev1: Sequences have not yet been collected for hRev1. 
v. Dpo4: On control DNA, Dpo4 exhibited a random spectrum of mutations. Dpo4 
exhibited a similar response to a cisplatin-dGpG adduct as hPolκ, displaying an increase in 
deletion mutations for 7 bases beginning at the site of the lesion (Appendix 3, Figures 6 and 7).  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  A.  
	  	  	  B.	  	  	  	  	     
Figure 4. Mutagenic spectra of polymerization by Dpo4 on A. 69-mer control DNA and B. 69-
mer CISP DNA. The relevant template sequences are denoted below the charts. 
	   58	  
As in Chapter 2, after sequence collection we calculated the total error frequency of 
polymerization. Both hPolκ and Dpo4 exhibited a 3-fold increase on damaged DNA. 
Discounting errors at the site of the lesion, total error frequency still increased 3-fold and 2-fold 
for hPolκ and Dpo4, respectively.   
Enzyme Total Error 
Frequency  
(69-mer control) 
Total Error 
Frequency  
(69-mer CISP) 
Total Error 
Frequency except 
cisplatin-dGpG site 
(69-mer CISP) 
hPolκ  1.8 x 10-2 5.8 x 10-2 4.8 x 10-2 
hPolη  -- -- -- 
hPolι  -- -- -- 
hRev1 -- -- -- 
Dpo4 1.1 x 10-2 3.1 x 10-2 2.5 x 10-2 
Table 2. Comparative error frequencies on 15/69-mer control and 15/69-mer CISP. 
In summary, we observed that hPolκ, hPolη, and Dpo4 are able to bypass a cisplatin-
dGpG adduct. Dpo4 and hPolκ exhibited a similar spectrum of mutations, primarily deletions 
around the site of the cisplatin-dGpG adduct. hPolη was the most efficient at cisplatin-dGpG 
bypass. Notably, hPolη generated lesion bypass products after 2 seconds, whereas hPolκ 
required ~90 seconds and Dpo4 required 4 seconds. Further results are forthcoming. 
Discussion 
 Lesion bypass is an essential process that enables the cell to continue DNA replication 
past DNA lesions. In tumors treated with cisplatin, a chemotherapeutic agent that harms cancer 
cells by creating DNA lesions, lesion bypass is a potential mechanism of drug resistance. The Y-
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family DNA polymerases are specialized for lesion bypass and are therefore suspected to bypass 
cisplatin-DNA adducts in vivo(41). In this study, we confirmed the ability of two human Y-family 
DNA polymerases and a model Y-family DNA polymerase to perform bypass of the most 
common cisplatin-DNA adduct. We also profiled the mutagenic spectra of cisplatin bypass by a 
human Y-family DNA polymerase and a model Y-family DNA polymerase. As in Chapter 2, the 
DNA polymerases studied displayed distinct lesion bypass mechanisms. Below, I will discuss 
our current results in light of current knowledge of each enzyme. 
 i. hPolη: We observed that hPolη was able to bypass a cisplatin-dGpG adduct with the 
highest efficiency of any of the DNA polymerases studied, generating lesion bypass product after 
2 seconds. hPolη exhibited the strongest pausing upon extension from the lesion. Previous 
studies indicate that this pausing may be due to misincorporation opposite the lesion. Kinetic 
studies noted that when hPolη inserted an incorrect nucleotide opposite the first dG of a cisplatin 
adduct it was not able to extend(46). Crystal structures of hPolη in complex with cisplatin-
containing DNA and incoming nucleotide suggest a higher propensity for misincorporation 
opposite G2 rather than G1. It is possible that hPolη is similarly not able to extend from 
misincorporations opposite G2. The combination of error-prone incorporation opposite G2 and 
lack of ability to extend from misincorporations may explain the strong pausing seen upon 
extension from the cisplatin-dGpG adduct(44).  
ii. hPolκ: We observed that hPolκ was able to bypass a cisplatin-dGpG adduct, though 
with a lower efficiency than either hPolη or Dpo4. It had particular difficulty incorporating a 
nucleotide opposite the first dG of the adduct. This may be due to similar difficulties that hPolκ 
exhibited on DNA containing a TT dimer in Chapter 2. Notably, hPolκ has the most constrained 
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active site of any of the human Y-family DNA polymerases(34). This likely enforces a strict steric 
requirement that hinders accommodation of the bulky cisplatin lesion. As in TT dimer bypass, 
hPolκ ably extended from the lesion. This is in accord with its ability to preferentially extend 
from nucleotides opposite a lesion(35).  
The primary change in the mutagenic spectrum of hPolκ due to the presence of a 
cisplatin-dGpG lesion was an increase in deletion mutations for 9 nucleotides around the site of 
the lesion. Though never observed for this large a stretch of DNA, previous studies have 
indicated that hPolκ can use primer/template misalignment to extend mismatched primer termini. 
Primer/template misalignment was the preferred route of mismatch extension when the template 
base was not present, as in extension from AP sites(47). It is possible that hPolκ is looping the 
intervening section containing the cisplatin-dGpG adduct out of its active site, then extending 
from a severely misaligned template. However, further structural and functional studies are 
needed to confirm this hypothesis. 
iii. Dpo4: We observed that Dpo4, the model Y-family DNA polymerase from Sulfolobus 
solfataricus, was able to efficiently bypass a cisplatin-dGpG lesion, generating bypass product 
after 4 seconds. Based on our running start assay, it appeared that Dpo4 stalled upon 
incorporation opposite both dGs of the cisplatin adduct, though more strongly opposite the 
second dG. Previous pre-steady state kinetic studies confirm this pattern, noting 72-fold and 860-
fold decreases in nucleotide incorporation efficiency at the first dG and the second dG, 
respectively(41). The ternary crystal structure of Dpo4 in complex with DNA containing a 
cisplatin-dGpG adduct and incoming nucleotide suggests structural reasons for loss of 
incorporation efficiency at each position. The first incorporation is hindered by the inability of 
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the template dG to optimally position itself; instead, it is being dragged towards the major groove 
by the second dG of the adduct. The second incorporation is hindered by unstable template dG 
positioning; though the template was observed to position itself optimally, another conformation 
existed in which template dG was tilted 10˚. This instability was hypothesized to have a greater 
effect than the non-ideal positioning of the first dG and to account for the dramatic decrease in 
incorporation efficiency opposite the second dG(48).  
The major change in error frequency due to the lesion was an increase in deletion 
frequency at the cisplatin-dGpG adduct and for the following 5 nucleotides. Interestingly, the 
aforementioned pre-steady state kinetic studies of Dpo4 bypassing a cisplatin lesion noted a 
decrease in incorporation efficiency both at the lesion and for six bases downstream(41). As with 
hPolκ, we hypothesize that this is due to the structural distortion of DNA due to the presence of a 
cisplatin lesion. Dpo4, also like hPolκ, has been shown to stabilize primer/template 
misalignments to generate deletion mutations(49). Though this was only observed for single base 
deletions, it is possible that a similar mechanism is being used to delete larger sections as seen in 
our sequence data. 
In summary, we used running start assays and short oligonucleotide sequencing assays to 
confirm that hPolκ, hPolη, and Dpo4 were able to bypass a cisplatin-dGpG adduct and to 
sequence the bypass products of hPolκ and Dpo4. hPolη was the most efficient at bypassing the 
lesion, though it stalled upon extension from the lesion. hPolκ had difficulty incorporating 
nucleotides opposite the first dG of the lesion, though it ably extended once the first nucleotide 
was incorporated. Dpo4 paused upon incorporation opposite both nucleotides of the lesion, 
though more strongly at the second nucleotide due to unstable template positioning. hPolκ and 
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Dpo4 exhibited similar changes in error frequency in response to the lesion, displaying dramatic 
increases in deletion mutations at the site of the lesion.  
On a final note, I remind the reader that the results related herein are preliminary and that 
both running start assays and SOSAs remain to be completed on the other human Y-family DNA 
polymerases. 
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Conclusion 
 In Chapter 1, we used pre-steady state kinetic methods to examine the ability of X-family 
human DNA polymerases lambda (hPolλ) and beta (hPolβ) to fill gaps in DNA. We found that 
hPolβ is able to maintain its nucleotide selection fidelity as gap size increased, though it suffered 
a loss of nucleotide incoporation efficiency. hPolλ exhibited the opposite trend, maintaining its 
nucleotide incorporation efficiency as gap size increased while suffering a loss of nucleotide 
selection fidelity. We hypothesize that the constant incorporation efficiency of hPolλ is due to its 
ability to loop downstream template DNA out of its active site while still maintaining contacts 
with both the primer terminus and the downstream end of the DNA gap. Finally, we determined 
that the N-terminal domains that differentiate hPolλ from hPolβ serve to downregulate the 
nucleotide selection fidelity of hPolλ on 2-10 nucleotide gaps. 
 In Chapter 2, we determined that all of the human Y-family DNA polymerases and Dpo4 
were able to bypass a cis-syn cyclobutane thymine dimer. hPolη bypassed the lesion most 
efficiently, in accordance with its proposed in vivo role in TT dimer bypass, followed by Dpo4, 
hPolκ, hPolι, and hRev1. We then sequenced the TT dimer bypass products using SOSAs, which 
are still in progress. hPolι and Dpo4 frequently skipped the site of the lesion, while hPolκ 
extended from substitution mutations opposite the lesion. Interestingly, hPolι displayed some of 
the same characteristic mutations seen in XPV cell lines, indicating it may take the place of 
hPolη when hPolη is nonfunctional.  
 In Chapter 3, we also determined that hPolη, hPolκ, and Dpo4 were able to bypass a 
cisplatin-dGpG adduct. hPolη did so most efficiently, in accord with its proposed role in 
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cisplatin bypass in vivo. hPolκ and Dpo4 tended to skip the site of the lesion, though running 
start assays once again showed the proficiency of hPolκ at extension from DNA lesions. This 
study is still in progress, as both running start assays and SOSAs need to be completed to obtain 
a full summary of cisplatin-dGpG bypass by the human Y-family DNA polymerases.  
 In short, this thesis details the main projects I worked on as an undergraduate in the Suo 
laboratory. These projects were mainly under the guidance of Jessica Brown and Shanen Sherrer. 
In addition to helping me mature as a scientist, I believe that these projects will contribute to our 
understanding of DNA repair and lesion bypass. 
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Appendix 1 
 
21-19/ 
41-mer 
 
21-19/ 
42-mer 
 
21-19/ 
43-mer 
 
21-19/ 
44-mer 
 
21-19/ 
45-mer 
 
21-19/ 
46-mer 
 
21-19/ 
47-mer 
 
21-19/ 
48-mer 
 
21-19/ 
49-mer 
 
21-19/ 
50-mer 
 
21-19T/ 
42-merCGA 
 
21-19/ 
42-merCAG 
 
21-19/ 
47-merCAT 
 
5’-CGCAGCCGTCCAACCAACTCApCGTCGATCCAATGCCGTCC-3’ 
3’-GCGTCGGCAGGTTGGTTGAGTCGCAGCTAGGTTACGGCAGG-5’ 
 
5’-CGCAGCCGTCCAACCAACTCA pCGTCGATCCAATGCCGTCC-3’ 
3’-GCGTCGGCAGGTTGGTTGAGTCGGCAGCTAGGTTACGGCAGG-5’ 
 
5’-CGCAGCCGTCCAACCAACTCA  pCGTCGATCCAATGCCGTCC-3’ 
3’-GCGTCGGCAGGTTGGTTGAGTCGAGCAGCTAGGTTACGGCAGG-5’ 
 
5’-CGCAGCCGTCCAACCAACTCA   pCGTCGATCCAATGCCGTCC-3’ 
3’-GCGTCGGCAGGTTGGTTGAGTCGAGGCAGCTAGGTTACGGCAGG-5’ 
 
5’-CGCAGCCGTCCAACCAACTCA    pCGTCGATCCAATGCCGTCC-3’ 
3’-GCGTCGGCAGGTTGGTTGAGTCGAGTGCAGCTAGGTTACGGCAGG-5’ 
 
5’-CGCAGCCGTCCAACCAACTCA     pCGTCGATCCAATGCCGTCC-3’ 
3’-GCGTCGGCAGGTTGGTTGAGTCGAGTGGCAGCTAGGTTACGGCAGG-5’ 
 
5’-CGCAGCCGTCCAACCAACTCA      pCGTCGATCCAATGCCGTCC-3’ 
3’-GCGTCGGCAGGTTGGTTGAGTCGAGTGCGCAGCTAGGTTACGGCAGG-5’ 
 
5’-CGCAGCCGTCCAACCAACTCA       pCGTCGATCCAATGCCGTCC-3’ 
3’-GCGTCGGCAGGTTGGTTGAGTCGAGTGCGGCAGCTAGGTTACGGCAGG-5’ 
 
5’-CGCAGCCGTCCAACCAACTCA        pCGTCGATCCAATGCCGTCC-3’ 
3’-GCGTCGGCAGGTTGGTTGAGTCGAGTGCGAGCAGCTAGGTTACGGCAGG-5’ 
 
5’-CGCAGCCGTCCAACCAACTCA         pCGTCGATCCAATGCCGTCC-3’ 
3’-GCGTCGGCAGGTTGGTTGAGTCGAGTGCGACGCAGCTAGGTTACGGCAGG-5’ 
 
5’-CGCAGCCGTCCAACCAACTCA pTGTCGATCCAATGCCGTCC-3’ 
3’-GCGTCGGCAGGTTGGTTGAGTCGACAGCTAGGTTACGGCAGG-5’ 
 
5’-CGCAGCCGTCCAACCAACTCA pCGTCGATCCAATGCCGTCC-3’ 
3’-GCGTCGGCAGGTTGGTTGAGTCAGCAGCTAGGTTACGGCAGG-5’ 
 
5’-CGCAGCCGTCCAACCAACTCA      pCGTCGATCCAATGCCGTCC-3’ 
3’-GCGTCGGCAGGTTGGTTGAGTCATGTGCGCAGCTAGGTTACGGCAGG-5’ 
Table 1. DNA substrates. pDenotes the 5′-end is phosphorylated. Oligonucleotides located in the 
gap are in bold, and those that were inserted to expand the gap size are underlined. 
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dNTP kp (s-1) Kd (µM) kp/Kd (µM-1s-1) 
Efficiency 
ratioa Fidelity
b 
21-19/41-mer (1-nucleotide gap) 
dGTP 2.7 ± 0.1 1.9 ± 0.2 1.4 -  
dCTP 0.00145 ± 0.00005 1.0 ± 0.1 1.5 × 10-3 - 1.0 × 10-3 
dATP 0.00047 ± 0.00002 0.9 ± 0.1 5.2 × 10-4 - 3.7 × 10-4 
dTTP 0.00135 ± 0.00009 2.9 ± 0.6 4.7 × 10-4 - 3.3 × 10-4 
21-19/42-mer (2-nucleotide gap) 
dGTP 1.77 ± 0.02 1.51 ± 0.06 1.2 1  
dCTP 0.0161 ± 0.0004 0.69 ± 0.08 2.3 × 10-2 16 ↑ 2.0 × 10-2 
dATP 0.00037 ± 0.00002 1.2 ± 0.2 3.1 × 10-4 2 ↑ 2.6 × 10-4 
dTTP 0.00070 ± 0.00003 3.8 ± 0.5 1.8 × 10-4 3 ↑ 1.6 × 10-4 
21-19/43-mer (3-nucleotide gap) 
dGTP 1.99 ± 0.06 1.5 ± 0.2 1.3 1  
dCTP 0.0079 ± 0.0002 0.79 ± 0.08 1.0 × 10-2 7 ↑ 7.5 × 10-3 
dATP 0.00044 ± 0.00003 0.6 ± 0.2 7.3 × 10-4 1 5.5 × 10-4 
dTTP 0.00095 ± 0.00008 2.8 ± 0.8 3.4 × 10-4 1 2.6 × 10-4 
21-19/44-mer (4-nucleotide gap) 
dGTP 1.64 ± 0.03 1.6 ± 0.1 1.0 1  
dCTP 0.0247 ± 0.0006 0.8 ± 0.1 3.1 × 10-2 21 ↑ 2.9 × 10-2 
dATP 0.00126 ± 0.00004 0.48 ± 0.07 2.6 × 10-3 5 ↑ 2.6 × 10-3 
dTTP 0.00129 ± 0.00007 2.8 ± 0.5 4.6 × 10-4 1 4.5 × 10-4 
21-19/45-mer (5-nucleotide gap) 
dGTP 2.15 ± 0.06 1.6 ± 0.2 1.3 1  
dCTP 0.053 ± 0.001 0.9 ± 0.1 5.9 × 10-2 41 ↑ 4.2 × 10-2 
dATP 0.0031 ± 0.0001 0.54 ± 0.07 5.7 × 10-3 11 ↑ 4.3 × 10-3 
dTTP 0.0118 ± 0.0006 2.7  ± 0.4 4.4 × 10-3 9 ↑ 3.2 × 10-3 
21-19/46-mer (6-nucleotide gap) 
dGTP 1.53 ± 0.06 0.7 ± 0.1 2.2 2 ↑  
dCTP 0.0450 ± 0.0008 0.79 ± 0.07 5.7 × 10-2 39 ↑ 2.5 × 10-2 
dATP 0.00149 ± 0.00002 0.46 ± 0.03 3.2 × 10-3 6 ↑ 1.5 × 10-3 
dTTP 0.0115 ± 0.0003 2.0  ± 0.2 5.8 × 10-3 12 ↑ 2.6 × 10-3 
21-19/47-mer (7-nucleotide gap) 
dGTP 1.86 ± 0.04 1.2 ± 0.1 1.6 1  
dCTP 0.049 ± 0.001 0.9 ± 0.1 5.4 × 10-2 38 ↑ 3.4 × 10-2 
dATP 0.00066 ± 0.00001 0.24 ± 0.02 2.8 × 10-3 5 ↑ 1.8 × 10-3 
dTTP 0.0051 ± 0.0002 1.1 ± 0.2 4.6 × 10-3 10 ↑ 3.0 × 10-3 
21-19/48-mer (8-nucleotide gap) 
dGTP 1.01 ± 0.03 1.6 ± 0.2 0.6 2 ↓  
dCTP 0.0082 ± 0.0002 0.47 ± 0.06 1.7 × 10-2 12 ↑ 2.7 × 10-2 
dATP 0.00023 ± 0.00001 0.8 ± 0.2 2.9 × 10-4 2 ↓ 4.6 × 10-4 
dTTP 0.00072 ± 0.00002 5.1 ± 0.4 1.4 × 10-4 3 ↓ 2.2 × 10-4 
21-19/49-mer (9-nucleotide gap) 
dGTP 0.83 ± 0.03 3.0 ± 0.3 0.3 5 ↓  
dCTP 0.00226 ± 0.00005 0.38 ± 0.05 5.9 × 10-3 4 ↓ 2.1 × 10-2 
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dATP No incorporation     
dTTP No incorporation     
21-19/50-mer (10-nucleotide gap) 
dGTP 0.026 ± 0.001 0.7 ± 0.1 3.7 × 10-2 38 ↓  
dCTP 0.00164 ± 0.00007 1.1 ± 0.2 1.5 × 10-3 1 3.9 × 10-2 
dATP No incorporation     
dTTP No incorporation     
21/41-mer (no gap) 
dGTP 0.0353 ± 0.0008 0.82 ± 0.08 4.3 × 10-2 33 ↓  
dCTP 0.00044 ± 0.00003 3.0 ± 0.7 1.5 × 10-4 10 ↓ 3.4 × 10-3 
dATP No incorporation     
dTTP No incorporation     
 
Table 2. Kinetic parameters for nucleotide incorporation into gapped and recessed DNA 
catalyzed by hPolλ at 37˚C. 
aAn upward-pointing arrow (↑) indicates the ratio was calculated as (kp/Kd)≥2-nucleotide gap/(kp/Kd)1-
nucleotide gap; a downward-pointing arrow (↓) indicates the calculation used a reciprocal of the 
equation as follows: (kp/Kd)1-nucleotide gap/(kp/Kd)≥2-nucleotide gap.  
bCalculated as (kp/Kd)incorrect/[(kp/Kd)correct + (kp/Kd)incorrect]. 
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dNTP kp (s-1) Kd (µM) kp/Kd (µM-1s-1) 
Efficiency 
ratioa Fidelity
b 
21-19/41mer (1-nucleotide gap) 
dGTP 3.1 ± 0.1 1.7 ± 0.2 1.8 -  
dCTP 0.00135 ± 0.00007 1.9 ± 0.4 7.1 × 10-4 - 3.9 × 10-4 
dATP 0.00066 ± 0.00007 1.8 ± 0.7 3.7 × 10-4 - 2.0 × 10-4 
dTTP 0.00130 ± 0.00009 7 ± 1 1.9 × 10-4 - 1.0 × 10-4 
21-19/42mer (2-nucleotide gap) 
dGTP 2.80 ± 0.05 1.24 ± 0.09 2.3 1  
dCTP 0.0208 ± 0.0005 0.85 ± 0.09 2.4 × 10-2 34 ↑ 1.1 × 10-2 
dATP 0.00031 ± 0.00002 3.0 ± 0.6 1.0 × 10-4 4 ↓ 4.6 × 10-5 
dTTP 0.00070 ± 0.00004 4.6 ± 0.7 1.5 × 10-4 1 6.7 × 10-5 
21-19/45mer (5-nucleotide gap) 
dGTP 3.83 ± 0.06 1.57 ± 0.09 2.4 1  
dCTP 0.0060 ± 0.0003 1.5 ± 0.2 4.0 × 10-3 6 ↑ 1.6 × 10-3 
dATP 0.00042 ± 0.00003 3.3 ± 0.6 1.3 × 10-4 3 ↓ 5.2 × 10-5 
dTTP 0.00154 ± 0.00009 7  ± 1 2.2 × 10-4 1 9.0 × 10-5 
21-19/47mer (7-nucleotide gap) 
dGTP 2.62 ± 0.05 1.28 ± 0.09 2.0 1  
dCTP 0.0072 ± 0.0002 0.77 ± 0.07 9.4 × 10-3 13 ↑ 4.5 × 10-3 
dATP 0.000102 ± 0.000008 2.1 ± 0.5 4.9 × 10-5 8 ↓ 2.4 × 10-5 
dTTP 0.0006 ± 0.0001 6 ± 3 1.0 × 10-4 2 ↓ 4.9 × 10-5 
21-19/50mer (10-nucleotide gap) 
dGTP 0.27 ± 0.01 2.4 ± 0.3 1.1 × 10-1 16 ↓  
dCTP 0.00019 ± 0.00001 5 ± 1 3.8 × 10-5 19 ↓ 3.4 × 10-4 
dATP No incorporation     
dTTP No incorporation     
21/41mer (no gap) 
dGTP 0.109 ± 0.007 1.7 ± 0.3 6.4 × 10-2 28 ↓  
dCTP 0.00030 ± 0.00002 4.2 ± 0.7 7.1 × 10-5 10 ↓ 1.1 × 10-3 
dATP No incorporation     
dTTP No incorporation     
 
Table 3. Kinetic parameters for nucleotide incorporation into gapped and recessed DNA 
catalyzed by dPolλ at 37˚C. 
aAn upward-pointing arrow (↑) indicates the ratio was calculated as (kp/Kd)≥2-nucleotide gap/(kp/Kd)1-
nucleotide gap; a downward-pointing arrow (↓) indicates the calculation used a reciprocal of the 
equation as follows: (kp/Kd)1-nucleotide gap/(kp/Kd)≥2-nucleotide gap.  
bCalculated as (kp/Kd)incorrect/[(kp/Kd)correct + (kp/Kd)incorrect]. 
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dNTP kp (s-1) Kd (µM) kp/Kd (µM-1s-1) 
Efficiency 
ratioa Fidelity
b 
21-19/41mer (1-nucleotide gap) 
dGTP 18.8 ± 0.4 8.7 ± 0.4 2.2 -  
dCTP 0.059 ± 0.002 140 ± 20 4.2 × 10-4 - 1.9 × 10-4 
dATP 0.32 ± 0.02 280 ± 60 1.1 × 10-3 - 5.3 × 10-4 
dTTP 0.27 ± 0.01 330 ± 40 8.2 × 10-4 - 3.7 × 10-4 
21-19/42mer (2-nucleotide gap) 
dGTP 39 ± 1 12 ± 2 3.3 1  
dCTP 0.0153 ± 0.0002 34 ± 3 4.5 × 10-4 1 1.4 × 10-4 
dATP 0.212 ± 0.009 200 ± 20 1.1 × 10-3 1 3.3 × 10-4 
dTTP 0.173 ± 0.009 340 ± 50 5.1 × 10-4 2 ↓ 1.6 × 10-4 
21-19/45mer (5-nucleotide gap) 
dGTP 36 ± 2 100 ± 10 3.6 × 10-1 6 ↓  
dCTP 0.065 ± 0.002 450 ± 30 1.4 × 10-4 3 ↓ 4.0 × 10-4 
dATP 0.0188 ± 0.0006 540 ± 40 3.5 × 10-5 33 ↓ 9.7 × 10-5 
dTTP 0.0117 ± 0.0008 900 ± 100 1.3 × 10-5 63 ↓ 3.6 × 10-5 
21-19/47mer (7-nucleotide gap) 
dGTP 37 ± 5 100 ± 30 3.7 × 10-1 6 ↓  
dCTP 0.203 ± 0.006 500 ± 40 4.1 × 10-4 1 1.1 × 10-3 
dATP 0.013 ± 0.002 800 ± 300 1.6 × 10-5 70 ↓ 4.4 × 10-5 
dTTP 0.0096 ± 0.0005 1400 ± 100 6.9 × 10-6 120 ↓ 1.9 × 10-5 
21-19/50mer (10-nucleotide gap) 
dGTP 10.5 ± 0.6 780 ± 90 1.3 × 10-2 160 ↓  
dCTP 0.0023 ± 0.0001 580 ± 60 4.0 × 10-6 110 ↓ 2.9 × 10-4 
dATP 0.00166 ± 0.00009 440 ± 60 3.8 × 10-6 300 ↓ 2.8 × 10-4 
dTTP 0.00090 ± 0.00006 620 ± 90 1.5 × 10-6 560 ↓ 1.1 × 10-4 
21/41mer (no gap) 
dGTP 31.4 ± 0.6 48 ± 2 6.5 × 10-1 3 ↓  
dCTP 0.024 ± 0.001 230 ± 30 1.0 × 10-4 4 ↓ 1.6 × 10-4 
dATP 0.111 ± 0.007 650 ± 90 1.7 × 10-4 7 ↓ 2.6 × 10-4 
dTTP 0.094 ± 0.005 1100 ± 100 8.5 × 10-5 10 ↓ 1.3 × 10-4 
 
Table 4. Kinetic parameters for nucleotide incorporation into gapped and recessed DNA 
catalyzed by hPolβ at 37˚C.  
aAn upward-pointing arrow (↑) indicates the ratio was calculated as (kp/Kd)≥2-nucleotide gap/(kp/Kd)1-
nucleotide gap; a downward-pointing arrow (↓) indicates the calculation used a reciprocal of the 
equation as follows: (kp/Kd)1-nucleotide gap/(kp/Kd)≥2-nucleotide gap.  
bCalculated as (kp/Kd)incorrect/[(kp/Kd)correct + (kp/Kd)incorrect]. 
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dNTP kp (s-1) Kd (µM) kp/Kd (µM-1s-1) 
Efficiency 
ratioa Fidelity
b 
21-19/41mer (1-nucleotide gap)c 
dGTP 4.1 ± 0.2 1.9 ± 0.4 2.2 -  
dCTP 0.0098 ± 0.0002 1.5 ± 0.2 6.5 × 10-3 - 3.0 × 10-3 
dATP 0.0046 ± 0.0001 1.4 ± 0.3 3.3 × 10-3 - 1.5 × 10-3 
dTTP 0.0065 ± 0.0001 4.7 ± 0.5 1.4 × 10-3 - 6.4 × 10-4 
21-19/42mer (2-nucleotide gap) 
dGTP 3.7 ± 0.2 2.3 ± 0.3 1.6 1  
dCTP 0.081 ± 0.001 1.12 ± 0.07 7.2 × 10-2 11 ↑ 4.3 × 10-2 
dATP 0.0019 ± 0.0002 2.4 ± 0.6 7.9 × 10-4 4 ↓ 4.9 × 10-4 
dTTP 0.0030 ± 0.0009 6 ± 3 5.0 × 10-4 3 ↓ 3.1 × 10-4 
21-19/45mer (5-nucleotide gap) 
dGTP 5.1 ± 0.2 3.3 ± 0.4 1.5 1  
dCTP 0.0123 ± 0.0003 1.4 ± 0.1 8.8 × 10-3 1 5.7 × 10-3 
dATP 0.0011 ± 0.0002 2 ± 1 5.5 × 10-4 6 ↓ 3.6 × 10-4 
dTTP 0.006 ± 0.002 9  ± 4 6.7 × 10-4 2 ↓ 4.3 × 10-4 
21-19/47mer (7-nucleotide gap) 
dGTP 3.78 ± 0.08 2.5 ± 0.2 1.5 1  
dCTP 0.028 ± 0.002 3.5 ± 0.8 8.0 × 10-3 1 5.3 × 10-3 
dATP 0.00035 ± 0.00002 1.6 ± 0.4 2.2 × 10-4 15 ↓ 1.4 × 10-4 
dTTP 0.0027 ± 0.0002 11 ± 2 2.5 × 10-4 6 ↓ 1.6 × 10-4 
21-19/50mer (10-nucleotide gap) 
dGTP 1.43 ± 0.05 5.1 ± 0.4 2.8 × 10-1 8 ↓  
dCTP 0.00067 ± 0.00006 5 ± 1 1.3 × 10-4 49 ↓ 4.8 × 10-4 
dATP 0.000350 ± 0.000009 3.6 ± 0.3 9.7 × 10-5 34 ↓ 3.5 × 10-4 
dTTP No incorporation     
21/41mer (no gap) 
dGTP 0.68 ± 0.02 2.0 ± 0.2 3.4 × 10-1 6 ↓  
dCTP 0.0007 ± 0.0001 5 ± 2 1.4 × 10-4 47 ↓ 4.1 × 10-4 
dATP No incorporation     
dTTP No incorporation     
 
Table 5. Kinetic parameters for nucleotide incorporation into gapped and recessed DNA 
catalyzed by tPolλ at 37˚C. 
aAn upward-pointing arrow (↑) indicates the ratio was calculated as (kp/Kd)≥2-nucleotide gap/(kp/Kd)1-
nucleotide gap; a downward-pointing arrow (↓) indicates the calculation used a reciprocal of the 
equation as follows: (kp/Kd)1-nucleotide gap/(kp/Kd)≥2-nucleotide gap.  
bCalculated as (kp/Kd)incorrect/[(kp/Kd)correct + (kp/Kd)incorrect]. 
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dNTP kp (s-1) Kd (µM) kp/Kd (µM-1s-1) 
Efficiency 
ratioa Fidelity
b 
21-19/41mer (1-nucleotide gap) 
dGTP 2.7 ± 0.1 1.9 ± 0.2 1.4 -  
dCTP 0.00145 ± 0.00005 1.0 ± 0.1 1.5 × 10-3 - 1.0 × 10-3 
dATP 0.00047 ± 0.00002 0.9 ± 0.1 5.2 × 10-4 - 3.7 × 10-4 
dTTP 0.00135 ± 0.00009 2.9 ± 0.6 4.7 × 10-4 - 3.3 × 10-4 
21-19/42mer (2-nucleotide gap) 
dGTP 1.77 ± 0.02 1.51 ± 0.06 1.2 1  
dCTP 0.0161 ± 0.0004 0.69 ± 0.08 2.3 × 10-2 16 ↑ 2.0 × 10-2 
dATP 0.00037 ± 0.00002 1.2 ± 0.2 3.1 × 10-4 2 ↓ 2.6 × 10-4 
dTTP 0.00070 ± 0.00003 3.8 ± 0.5 1.8 × 10-4 3 ↓ 1.6 × 10-4 
21-19T/42merCGA (2-nucleotide gap) 
dGTP 2.4 ± 0.1 2.4 ± 0.4 1 1  
dCTP 0.0305 ± 0.0007 0.52 ± 0.06 5.9 × 10-2 40 ↑ 5.5 × 10-2 
dATP 0.00069 ± 0.00003 0.6 ± 0.1 1.2 × 10-3 2 ↑ 1.1 × 10-3 
dTTP 0.00075 ± 0.00004 3.3 ± 0.7 2.3 × 10-4 2 ↓ 2.3 × 10-4 
21-19/42merCAG (2-nucleotide gap) 
dGTP 2.9 ± 0.1 1.7 ± 0.3 1.7 1  
dCTP 0.00076 ± 0.00007 1.7 ± 0.5 4.5 × 10-4 3 ↓ 2.6 × 10-4 
dATP 0.00049 ± 0.00002 0.9 ± 0.2 5.4 × 10-4 1  3.2 × 10-4 
dTTP 0.0025 ± 0.0002 4.4 ± 0.8 5.7 × 10-4 1 3.3 × 10-4 
21-19/47mer (7-nucleotide gap) 
dGTP 1.86 ± 0.04 1.2 ± 0.1 1.6 1  
dCTP 0.049 ± 0.001 0.9 ± 0.1 5.4 × 10-2 38 ↑ 3.4 × 10-2 
dATP 0.00066 ± 0.00001 0.24 ± 0.02 2.8 × 10-3 5 ↑ 1.8 × 10-3 
dTTP 0.0051 ± 0.0002 1.1 ± 0.2 4.6 × 10-3 10 ↑ 3.0 × 10-3 
21-19/47merCAT (7-nucleotide gap) 
dGTP 3.3 ± 0.2  3.1 ± 0.6 1.1 1  
dCTP 0.0087 ± 0.0001 0.58 ± 0.03 1.5 × 10-2 10 ↑ 1.4 × 10-2 
dATP 0.0045 ± 0.0001 1.2 ± 0.1 3.8 × 10-3 7 ↑ 3.5 × 10-3 
dTTP 0.146 ± 0.002 2.5 ± 0.1 5.8 × 10-2 125 ↑ 5.2 × 10-2 
 
Table 6. Kinetic parameters for nucleotide incorporation into gapped DNA catalyzed by hPolλ at 
37˚C.  
aAn upward-pointing arrow (↑) indicates the ratio was calculated as (kp/Kd)≥2-nucleotide gap/(kp/Kd)1-
nucleotide gap; a downward-pointing arrow (↓) indicates the calculation used a reciprocal of the 
equation as follows: (kp/Kd)1-nucleotide gap/(kp/Kd)≥2-nucleotide gap.  
bCalculated as (kp/Kd)incorrect/[(kp/Kd)correct + (kp/Kd)incorrect]. 
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dNTP kp (s-1) Kd (µM) kp/Kd (µM-1s-1) 
Efficiency 
ratioa Fidelity
b 
21-19/41mer (1-nucleotide gap) 
dGTP 18.8 ± 0.4 8.7 ± 0.4 2.2 -  
dCTP 0.059 ± 0.002 140 ± 20 4.2 × 10-4 - 1.9 × 10-4 
dATP 0.32 ± 0.02 280 ± 60 1.1 × 10-3 - 5.3 × 10-4 
dTTP 0.27 ± 0.01 330 ± 40 8.2 × 10-4 - 3.7 × 10-4 
21-19/42mer (2-nucleotide gap) 
dGTP 39 ± 1 12 ± 2 3.3 1  
dCTP 0.0153 ± 0.0002 34 ± 3 4.5 × 10-4 1 1.4 × 10-4 
dATP 0.212 ± 0.009 200 ± 20 1.1 × 10-3 1 3.3 × 10-4 
dTTP 0.173 ± 0.009 340 ± 50 5.1 × 10-4 2 ↓ 1.6 × 10-4 
21-19T/42merCGA (2-nucleotide gap) 
dGTP 41 ± 4 10 ± 3 4.1 2 ↑  
dCTP 0.041 ± 0.006 300 ± 100 1.4 × 10-4 3 ↓ 3.3 × 10-5 
dATP 0.094 ± 0.005 190 ± 30 4.9 × 10-4 2 ↓ 1.2 × 10-4 
dTTP 0.26 ± 0.07 1500 ± 600 1.7 × 10-4 5 ↓ 4.2 × 10-5 
21-19/42merCAG (2-nucleotide gap) 
dGTP 44 ± 1 10 ± 1 4.4 2 ↑  
dCTP 0.072 ± 0.004 340 ± 60 2.1 × 10-4 2 ↓ 4.8 × 10-5 
dATP 0.180 ± 0.008 140 ± 20 1.3 × 10-3 1  2.9 × 10-4 
dTTP 0.0103 ± 0.0003 17 ± 2 6.1 × 10-4 1 1.4 × 10-4 
21-19/47mer (7-nucleotide gap) 
dGTP 37 ± 5 100 ± 30 3.7 × 10-1 6 ↓  
dCTP 0.203 ± 0.006 500 ± 40 4.1 × 10-4 1 1.1 × 10-3 
dATP 0.013 ± 0.002 800 ± 300 1.6 × 10-5 70 ↓ 4.4 × 10-5 
dTTP 0.0096 ± 0.0005 1400 ± 100 6.9 × 10-6 120 ↓ 1.9 × 10-5 
21-19/47merCAT (7-nucleotide gap) 
dGTP 32 ± 4  230 ± 60  1.4 × 10-1 16 ↓  
dCTP 0.0116 ± 0.0009 1200 ± 200 9.7 × 10-6 44 ↓ 6.9 × 10-5 
dATP 0.04 ± 0.01 1300 ± 700 3.1 × 10-5 37 ↓ 2.2 × 10-4 
dTTP 0.0113 ± 0.0003 850 ± 40 1.3 × 10-5 62 ↓ 9.6 × 10-5 
 
Table 7. Kinetic parameters for nucleotide incorporation into gapped DNA catalyzed by hPolβ at 
37˚C. 
aAn upward-pointing arrow (↑) indicates the ratio was calculated as (kp/Kd)≥2-nucleotide gap/(kp/Kd)1-
nucleotide gap; a downward-pointing arrow (↓) indicates the calculation used a reciprocal of the 
equation as follows: (kp/Kd)1-nucleotide gap/(kp/Kd)≥2-nucleotide gap.  
bCalculated as (kp/Kd)incorrect/[(kp/Kd)correct + (kp/Kd)incorrect]. 
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dNTP kp (s-1) Kd (µM) kp/Kd (µM-1s-1) 
Efficiency 
ratioa Fidelity
b 
21-19/41mer (1-nucleotide gap) 
dGTP 3.1 ± 0.1 1.7 ± 0.2 1.8 -  
dCTP 0.00135 ± 0.00007 1.9 ± 0.4 7.1 × 10-4 - 3.9 × 10-4 
dATP 0.00066 ± 0.00007 1.8 ± 0.7 3.7 × 10-4 - 2.0 × 10-4 
dTTP 0.00130 ± 0.00009 7 ± 1 1.9 × 10-4 - 1.0 × 10-4 
21-19/42mer (2-nucleotide gap) 
dGTP 2.80 ± 0.05 1.24 ± 0.09 2.3 1  
dCTP 0.0208 ± 0.0005 0.85 ± 0.09 2.4 × 10-2 34 ↑ 1.1 × 10-2 
dATP 0.00031 ± 0.00002 3.0 ± 0.6 1.0 × 10-4 4 ↓ 4.6 × 10-5 
dTTP 0.00070 ± 0.00004 4.6 ± 0.7 1.5 × 10-4 1 6.7 × 10-5 
21-19T/42merCGA (2-nucleotide gap) 
dGTP 2.57 ± 0.08 0.9 ± 0.1 2.9 1  
dCTP 0.0200 ± 0.0006 0.80 ± 0.07 2.5 × 10-2 35 ↑ 8.7 × 10-3 
dATP 0.00027 ± 0.00002 1.3 ± 0.4 2.1 × 10-4 2 ↓ 7.3 × 10-5 
dTTP 0.00024 ± 0.00002 3.3 ± 0.8 7.3 × 10-5 3 ↓ 2.5 × 10-5 
21-19/42merCAG (2-nucleotide gap) 
dGTP 3.9 ± 0.2 1.6 ± 0.3 2.4 1  
dCTP 0.00116 ± 0.00008 2.3 ± 0.5 5.0 × 10-4 1  2.1 × 10-4 
dATP 0.00030 ± 0.00003 2.5 ± 0.8 1.2 × 10-4 3 ↓ 4.9 × 10-5 
dTTP 0.0027 ± 0.0002 4.0 ± 0.9 6.8 × 10-4 4 ↑ 2.8 × 10-4 
 
Table 8. Kinetic parameters for nucleotide incorporation into gapped DNA catalyzed by dPolλ at 
37˚C. 
aAn upward-pointing arrow (↑) indicates the ratio was calculated as (kp/Kd)≥2-nucleotide gap/(kp/Kd)1-
nucleotide gap; a downward-pointing arrow (↓) indicates the calculation used a reciprocal of the 
equation as follows: (kp/Kd)1-nucleotide gap/(kp/Kd)≥2-nucleotide gap.  
bCalculated as (kp/Kd)incorrect/[(kp/Kd)correct + (kp/Kd)incorrect]. 
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dNTP kp (s-1) Kd (µM) kp/Kd (µM-1s-1) 
Efficiency 
ratioa Fidelity
b 
21-19/41mer (1-nucleotide gap)c 
dGTP 4.1 ± 0.2 1.9 ± 0.4 2.2 -  
dCTP 0.0098 ± 0.0002 1.5 ± 0.2 6.5 × 10-3 - 3.0 × 10-3 
dATP 0.0046 ± 0.0001 1.4 ± 0.3 3.3 × 10-3 - 1.5 × 10-3 
dTTP 0.0065 ± 0.0001 4.7 ± 0.5 1.4 × 10-3 - 6.4 × 10-4 
21-19T/42mer (2-nucleotide gap) 
dGTP 3.7 ± 0.2 2.3 ± 0.3 1.6 1  
dCTP 0.081 ± 0.001 1.12 ± 0.07 7.2 × 10-2 11 ↑ 4.3 × 10-2 
dATP 0.0019 ± 0.0002 2.4 ± 0.6 7.9 × 10-4 4 ↓ 4.9 × 10-4 
dTTP 0.0030 ± 0.0009 6 ± 3 5.0 × 10-4 3 ↓ 3.1 × 10-4 
21-19/42merCGA (2-nucleotide gap) 
dGTP 4.8 ± 0.1 2.1 ± 0.2 2.3 1  
dCTP 0.141 ± 0.003 0.78 ± 0.06 1.8 × 10-1 28 ↑ 7.3 × 10-2 
dATP 0.0014 ± 0.0001 1.3 ± 0.3 1.1 × 10-3 3 ↓ 4.7 × 10-4 
dTTP 0.0028 ± 0.0002 5 ± 2 5.6 × 10-4 2 ↓ 2.4 × 10-4 
21-19/42merCAG (2-nucleotide gap) 
dGTP 4.6 ± 0.2 2.6 ± 0.4 1.8 1  
dCTP 0.0064 ± 0.0003 1.3 ± 0.2 4.9 × 10-3 1  2.8 × 10-3 
dATP 0.002 ± 0.0001 1.3 ± 0.3 1.5 × 10-3 2 ↓ 8.7 × 10-4 
dTTP 0.016 ± 0.001 4.3 ± 0.9 3.7 × 10-3 3 ↑ 2.1 × 10-3 
 
Table 9. Kinetic parameters for nucleotide incorporation into gapped DNA catalyzed by tPolλ at 
37˚C. 
aAn upward-pointing arrow (↑) indicates the ratio was calculated as (kp/Kd)≥2-nucleotide gap/(kp/Kd)1-
nucleotide gap; a downward-pointing arrow (↓) indicates the calculation used a reciprocal of the 
equation as follows: (kp/Kd)1-nucleotide gap/(kp/Kd)≥2-nucleotide gap.  
bCalculated as (kp/Kd)incorrect/[(kp/Kd)correct + (kp/Kd)incorrect]. 
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Figure 1. Model of template scrunching and stabilization of misalignment by hPolλ. 
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Appendix 2 
	    
Figure 1. A. Running start assay of hPolη on 17/77-mer control, B. On 17/77-mer TT. “17” 
denotes the primer band, “27” T1 of the TT dimer, “28” T2 of the TT dimer, and “66” full length 
product. 
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Figure 2. A. Running start assay of hPolκ on 17/77-mer control DNA, B. On 17/77-mer TT 
DNA. “17” denotes the primer band, “27” T1 of the TT dimer, “28” T2 of the TT dimer, and 
“66” full length product. 
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Figure 3. A. Running start assay of hPolι on 17/77-mer control DNA, B. On 17/77-mer TT 
DNA. “17” denotes the primer band, “27” T1 of the TT dimer, “28” T2 of the TT dimer, and 
“66” full length product. 
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Figure 4. A. Running start assay of hRev1 on 17/77-mer control DNA, B. On 17/77-mer TT 
DNA. “17” denotes the primer band, T1 and T2 of the TT dimer are indicated and “66” full 
length product. 
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Figure 5. A. Running start assay of Dpo4 on 17/77-mer control DNA, B. On 17/77-mer TT 
DNA. “17” denotes the primer band, “27” T1 of the TT dimer, “28” T2 of the TT dimer, and 
“66” full length product. 
 
 
CGGCATCAGCAATGTTGACCCAACTCAATGTCGATCCAATGGAGGCGTGCTGTGCGAGCGGATAGG (2/11) 
                      T                                            (2/11)   
                 A              G                                  (2/11) 
                         T                                         (1/11) 
                          T   G                                    (1/11) 
                C     C      C                                     (1/11) 
              A              G                                     (1/11) 
                      G                                            (1/11) 
                A     C   AA     T  T    CCAAT                     (1/11) 
 
Figure 6. Mutagenic profile for hPolη’s replication of 17/77-mer control DNA. Individual base 
substitutions (purple), deletions (green), and insertions (blue) are shown. The sequencing 
window is in bold. 
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CGGCATCAGCAATGTTGACCCAACTCAATGTCGATCCAATGGAGGCGTGCTGTGCGAGCGGATAGG (10/25) 
                    CA                                             (5/25) 
                      C         A     A  A                         (1/25) 
                      C               A  A                         (1/25) 
                                         T  C                      (1/25) 
                                 C                                 (1/25) 
                       G        G                                  (1/25) 
                            C                                      (1/25) 
                          TTC                                      (1/25) 
                      C     C                                      (1/25) 
                                 C  A     AGG                      (1/25) 
                              GAC   A     T G                      (1/25) 
 
Figure 7. Mutagenic profile for hPolκ’s replication of 17/77-mer control DNA. Individual base 
substitutions (purple), deletions (green), and insertions (blue) are shown. The sequencing 
window is in bold. 
 
 
CGGCATCAGCAATGTTGACCCAACTCAATGTCGATCCAATGGAGGCGTGCTGTGCGAGCGGATAGG (0/14) 
                     G    TG   GT                                  (4/14) 
                     G    AA                                       (2/14) 
                            A                                      (1/14) 
                          AA        A                              (1/14)         
                  A      C  T                A                     (1/14) 
                                        A                          (1/14) 
              T           TC C TA   C C     A                      (1/14) 
                          AA    A                                  (1/14) 
                          TC C TT     C                            (1/14) 
                          AA                CG                     (1/14) 
 
Figure 8. Mutagenic profile for hPolκ’s replication of 17/77-mer TT DNA. Individual base 
substitutions (purple), deletions (green), and insertions (blue) are shown. The sequencing 
window is in bold. The site of the TT dimer is in red. 
 
 
CGGCATCAGCAATGTTGACCCAACTCAATGTCGATCCAATGGAGGCGTGCTGTGCGAGCGGATAGG (0/6) 
                  A      T      A          A                       (1/6) 
                           C               A                       (1/6) 
                      T    C                                       (1/6) 
                     T    GC  C     CA      A               A      (1/6) 
                          AA             G A                       (1/6) 
                          T C   T          A                       (1/6) 
 
Figure 9. Mutagenic profile for hPolι’s replication of 17/77-mer control DNA. Individual base 
substitutions (purple), deletions (green), and insertions (blue) are shown. The sequencing 
window is in bold. 
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CGGCATCAGCAATGTTGACCCAACTCAATGTCGATCCAATGGAGGCGTGCTGTGCGAGCGGATAGG (0/21) 
                          AA                                       (11/21) 
                     G    AA    T    TG   T                        (2/21)   
                          TA CCCG    CG   GT                       (1/21) 
                 C        AA    T T TTTG  ACC G T                  (1/21) 
                     G    AA   TG   TG   G T                       (1/21) 
                     CT   AA   C     A                             (1/21) 
                          AA   C             C                     (1/21) 
                     G    AA    T     A T                          (1/21) 
                     G    AA    TA   TT   G                        (1/21) 
                     T    AA    T     G                            (1/21) 
 
                      
Figure 10. Mutagenic profile for hPolι’s replication of 17/77-mer TT DNA. Individual base 
substitutons (purple), deletions (green), and insertions (blue) are shown. The sequencing window 
is in bold. The site of the TT dimer is in red. 
 
 
 
CGGCATCAGCAATGTTGACCCAACTCAATGTCGATCCAATGGAGGCGTGCTGTGCGAGCGGATAGG (61/65) 
                                     G                             (2/65) 
                           G                                       (1/65) 
                                            C                      (1/65) 
 
Figure 11. Mutagenic profile for Dpo4’s replication of 17/77-mer control DNA. Individual base 
substitutions (purple), deletions (green), and insertions (blue) are shown. The sequencing 
window is in bold. 
 
 
 
CGGCATCAGCAATGTTGACCCAACTCAATGTCGATCCAATGGAGGCGTGCTGTGCGAGCGGATAGG (8/28) 
                          AA                                       (9/28) 
                           C                                       (4/28)   
                  G       AA                                       (2/28)                                
                           C      T                                (1/28) 
                     CT   AA                                       (1/28) 
                          AA  C            T                       (1/28) 
                       C                                           (1/28) 
                          GA  T  A    A CAT  T                     (1/28) 
 
Figure 12. Mutagenic profile for Dpo4’s replication of 17/77-mer TT DNA. Individual base 
substitutions (purple), deletions (green), and insertions (blue) are shown. The sequencing 
window is in bold. The site of the TT dimer is in red. 
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Appendix 3 
 
 
Figure 1. A. Running start assay of hPolη on 15/69-mer control DNA, B. On 15/69-mer CISP 
DNA. “15” denotes the primer band, “24” G1 of the cisplatin adduct, “25” G2 of the cisplatin 
adduct, and “54” full length product. 
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Figure 2. A. Running start assay of hPolκ on 15/69-mer control DNA, B. On 15/69-mer CISP 
DNA. “15” denotes the primer band, “24” G1 of the cisplatin adduct, “25” G2 of the cisplatin 
adduct, and “54” full length product. 
 
Figure 3. A. Running start assay of Dpo4 on 15/69-mer control DNA, B. On 15/69-mer CISP 
DNA. “15” denotes the primer band, “24” G1 of the cisplatin adduct, “25” G2 of the cisplatin 
adduct, and “54” full length product. 
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Figure 4. Mutagenic profile for hPolκ’s replication of 15/69-mer control. Individual base 
substitutions (dark blue), deletions (light blue), and insertions (orange) are shown. The 
sequencing window is underlined. 
 
 
Figure 5. Mutagenic profile for hPolκ’s replication of 15/69-mer CISP. Individual base 
substitutions (dark blue), deletions (light blue), and insertions (orange) are shown. The 
sequencing window is underlined. The site of the cisplatin-dGpG adduct is in red. 
	   86	  
 
Figure 6. Mutagenic profile for Dpo4’s replication of 15/69-mer control. Individual base 
substitutions (dark blue), deletions (light blue), and insertions (orange) are shown. The 
sequencing window is underlined. 
 
 
Figure 7. Mutagenic profile for Dpo4’s replication of 15/69-mer CISP. Individual base 
substitutions (dark blue), deletions (light blue), and insertions (orange) are shown. The 
sequencing window is underlined. The site of the cisplatin-dGpG adduct is in red. 
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